<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1908200131
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Bexsero
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN THE NHBA,RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN THE NHBA I,RECOMBINANT N MENINGITIDIS SEROGROUP B NADA PROTEIN,RECOMBINANT N MENINGITIDIS SEROGROUP B NADA PROTEIN I,RECOMBINANT N MENINGITIDIS SEROGROUP B FHBP FUSION PROTEIN,RECOMBINANT N MENINGITIDIS SEROGROUP B FHBP FUSION PROTEIN I,OUTER MEMBRANE VESICLES FROM N MENINGITIDIS SEROGROUP B STRAIN NZ98254
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50,50,50,50,50,50,50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension for injection in pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        347.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GSK Vaccines Srl" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GSK Vaccines Srl
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07AH09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Bexsero is a Meningococcal group B Vaccine.</p><p>Bexsero contains four different components from the surface of the bacteria <em>Neisseria meningitidis </em>group B.</p><p>&nbsp;</p><p>Bexsero is given to individuals from 2 months of age and older to help protect against disease caused by the <em>Neisseria meningitidis </em>group B bacteria. These bacteria can cause serious, and sometimes life-threatening, infections such as meningitis (inflammation of the covering of the brain and spinal cord) and sepsis (blood poisoning).</p><p>&nbsp;</p><p>As with all vaccines, Bexsero may not fully protect all people who are vaccinated.</p><p>&nbsp;</p><p>Bexsero helps your body make its own protection (antibodies). This will protect you against this disease.</p><p>The vaccine cannot cause the disease that it protects you from.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Bexsero should not be given</strong><!--[if supportFields]><b><span lang=EN-GB
style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_eda674c6-c7f9-4951-9c85-f56714f35fad \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to Bexsero or any of the ingredients contained in Bexsero (listed in section 6). Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.</p><p>Check with your doctor if you think any of these apply to you.</p><p><strong>Take special care with Bexsero</strong><!--[if supportFields]><b><span lang=EN-GB
style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_79dc7ed5-0a5a-4e13-994f-a674b561f55f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Your doctor needs to know before you receive Bexsero:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe infection with a high temperature. In these cases, the vaccination may be postponed until recovery. A minor infection such as a cold should not be a problem, but talk to your doctor first.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you receive treatment that blocks the part of the immune system known as complement activation, such as eculizumab. Even if you have been vaccinated with Bexsero you remain at increased risk of disease caused by the <em>Neisseria meningitidis </em>group B bacteria.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your child was born prematurely (before or at 28 weeks of pregnancy), particularly if they had breathing difficulties, please tell your doctor. Stopping breathing or irregular breathing for a short time may be more common in the first three days following vaccination in these babies and they may need special monitoring.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an allergy to the antibiotic kanamycin, talk to your doctor or nurse first.</p><p>&nbsp;</p><p>Fainting can occur following, or even before, any needle injection, therefore tell the doctor or nurse if you fainted with a previous injection.</p><p>&nbsp;</p><p>The safety and efficacy of Bexsero in individuals above 50 years of age have not been established. There are limited data on the use of Bexsero in patients with chronic medical conditions or with weakened immunity. Persons with a weakened immune system, for example due to HIV infection or due to medicines that suppress the immune system, may not get the full benefit from Bexsero.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Using other medicines or vaccines</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_e79bc229-7e41-4dcb-9a42-9dbf27456b92 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Tell your doctor or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or have recently received any other vaccine.</p><p>&nbsp;</p><p>Bexsero can be given at the same time as any of the following vaccine components: diphtheria, tetanus, whooping cough (pertussis), <em>Haemophilus influenzae </em>type b, polio, hepatitis B, pneumococcus, measles, mumps, rubella, chickenpox, and meningococcus A, C, W, Y. A different injection site will be used for each type of vaccine.</p><p>&nbsp;</p><p>Your doctor or nurse may ask you to give your child medicines that lower fever at the time and after Bexsero has been given. This will help to reduce some of the side effects of Bexsero.</p><p><strong>Pregnancy and breast-feeding</strong><!--[if supportFields]><b><span lang=EN-GB
style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ebba290d-6590-4e5d-ba56-c30736c2e878 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong><!--[if supportFields]><b><span lang=EN-GB
style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_e44a5e59-1e65-46b1-80e9-b3448272a49e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Bexsero has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under section 4 &ldquo;Possible side effects&rdquo; may temporarily</p><p>affect the ability to drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How Bexsero is given</strong><!--[if supportFields]><b><span lang=EN-GB style='font-size:
12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_282ad52f-e27e-4093-96cb-29e7a949a4ad \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Bexsero (0.5 mL) will be given to you by a doctor or nurse. It will be injected into a muscle, usually the thigh for infants or the upper arm for children, adolescents and adults. It is important to follow the instructions from the doctor or nurse so that you complete the course of injections.</p><p>&nbsp;</p><p><em>Infants 2 months to 5 months of age at the time of first dose</em></p><p><em>&nbsp;</em></p><p>Your child should receive an initial course of two or three injections of the vaccine followed by an additional injection (booster).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The interval between injections should be at least 2 months if two initial doses are given or at least 1 month if three initial doses are given.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A booster will be given in the second year of life after an interval of at least 6 months from the last injection of the initial course.</p><p>&nbsp;</p><p><em>Infants 6 months to 11 months of age at the time of first dose</em></p><p><em>&nbsp;</em></p><p>Infants 6 months to 11 months of age should receive two injections of the vaccine followed by an additional injection (booster).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The interval between each injection should be at least 2 months.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A booster will be given in the second year of life after an interval of at least 2 months from the second injection.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Children 12 months to 23 months of age at the time of first dose</em></p><p><em>&nbsp;</em></p><p>Children 12 months to 23 months of age should receive two injections of the vaccine followed by an additional injection (booster).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The interval between each injection should be at least 2 months.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A booster will be given after an interval of 12 to 23 months from the second injection.</p><p>&nbsp;</p><p><em>Children 2 years to 10 years of age at the time of first dose</em></p><p><em>&nbsp;</em></p><p>Your child should receive two injections of the vaccine with an interval of at least 1 month.</p><p>Your child may receive an additional injection (booster).</p><p>&nbsp;</p><p><em>Adolescents and adults from 11 years of age at the time of first dose</em></p><p><em>&nbsp;</em></p><p>You should receive two injections of the vaccine with an interval of at least 1 month. You may receive an additional injection (booster).</p><p>&nbsp;</p><p><em>Adults above 50 years of age</em></p><p><em>&nbsp;</em></p><p>The safety and efficacy of Bexsero in individuals above 50 years of age have not been established. Ask your doctor for advice whether it is beneficial for you to receive Bexsero.</p><p>&nbsp;</p><p>If you have any further questions on Bexsero, ask your doctor or nurse.</p><p>&nbsp;</p><p><strong>If you miss a dose of Bexsero</strong><!--[if supportFields]><b><span lang=EN-GB
style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_131ff7e5-d93f-433f-bc43-3632a490f860 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>If you miss a scheduled injection, it is important that you make another appointment.</p><p>&nbsp;</p><p>Make sure you finish the complete vaccination course. If not, you may not be fully protected against the diseases.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Bexsero can cause side effects, although not everyone gets them.</p><p>&nbsp;</p><p><em>All age groups</em></p><p><em>&nbsp;</em></p><p>When Bexsero is given to you or your child, the very common side effects (may affect more than 1 in 10 people) that you or your child may get (reported in all age groups) are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain/tenderness at the injection site, redness of the skin at the injection site, swelling of the skin at the injection site, hardness of the skin at the injection site.</p><p>&nbsp;</p><p>The following side effects may also occur after receiving this vaccine:</p><p>&nbsp;</p><p><em>Infants and children (up to 10 years of age)</em></p><p><em>&nbsp;</em></p><p><strong>Very common </strong>(these may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (&ge;38&ordm;C)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tenderness at the injection site (including severe injection site tenderness resulting in crying when injected limb is moved)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash (children aged 12 to 23 months) (uncommon after booster)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling irritable</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual crying</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting (uncommon after booster)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&nbsp;</p><p><strong>Common </strong>(these affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash (infants and children 2 to 10 years of age)</p><p>&nbsp;</p><p><strong>Uncommon </strong>(these affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high fever (&ge;40&deg;C)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures (including febrile seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paleness (rare after booster)</p><p>&nbsp;</p><p><strong>Rare </strong>(these affect up to 1 in 1000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kawasaki disease which may include symptoms such as fever that lasts for more than five days, associated with a skin rash on the trunk of the body, and sometimes followed by a peeling of the skin on the hands and fingers, swollen glands in the neck, red eyes, lips, throat and tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy rash, skin rash</p><p><em>Adolescents (from 11 years of age) and adults</em></p><p><em>&nbsp;</em></p><p><strong>Very common </strong>(these may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the injection site resulting in inability to perform normal daily activity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful muscles and joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Post-marketing data</em></p><p>Side effects that have been reported during marketed use include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged lymph nodes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions that may include severe swelling of the lips, mouth, throat (which may cause difficulty in swallowing), difficulty breathing with wheezing or coughing, rash, loss of consciousness and very low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse (sudden onset of muscle floppiness), less responsive than usual or lack of awareness, and paleness or bluish skin discoloration in young children; feeling faint or fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash (adolescents from 11 years of age and adults)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (adolescents from 11 years of age and adults); injection site reactions like extensive swelling of the vaccinated limb, blisters at or around the injection site and hard lump at the injection site (which may persist for more than one month)</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children. Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Bexsero contains</strong><!--[if supportFields]><b><span lang=EN-GB style='font-size:
12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3c586d93-937d-4b2e-b150-b06eef1e9e79 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-ansi-language:EN-GB;
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>1 dose (0.5 mL) contains:</p><p>&nbsp;</p><p><em>The active substances are:</em></p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Recombinant <em>Neisseria meningitidis</em> group B NHBA fusion protein&nbsp;<sup>1,&nbsp;2,&nbsp;3</sup></p></td><td style="vertical-align:bottom"><p>50&nbsp;micrograms</p></td></tr><tr><td style="vertical-align:top"><p>Recombinant <em>Neisseria meningitidis </em>group B NadA protein&nbsp;<sup>1,&nbsp;2,&nbsp;3</sup></p></td><td style="vertical-align:bottom"><p>50&nbsp;micrograms</p></td></tr><tr><td style="vertical-align:top"><p>Recombinant <em>Neisseria meningitidis</em> group B fHbp fusion protein&nbsp;<sup>1,&nbsp;2,&nbsp;3</sup></p></td><td style="vertical-align:bottom"><p>50&nbsp;micrograms</p></td></tr><tr><td style="vertical-align:bottom"><p>Outer membrane vesicles (OMV) from <em>Neisseria meningitidis </em>group B</p><p>strain NZ98/254&nbsp;measured as amount of total protein containing the PorA P1.4&nbsp;<sup>2</sup></p></td><td style="vertical-align:bottom"><p>25&nbsp;micrograms</p></td></tr></tbody></table><p><sup>&nbsp;</sup></p><p><sup>1</sup>produced in <em>E. coli</em> cells by recombinant DNA technology</p><p><sup>2</sup>Adsorbed on aluminium hydroxide (0.5 mg Al<sup>3+</sup>)</p><p><sup>3</sup>NHBA (Neisserial Heparin Binding Antigen), NadA (<em>Neisseria</em> adhesin A), fHbp (factor H binding protein)</p><p>&nbsp;</p><p><em>The other ingredients are:</em></p><p>Sodium chloride, histidine, sucrose, water for injections</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>-</strong><strong>GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p>To report any side effect(s):</p><p dir="RTL"><strong><em>Kingdom of Saudi Arabia</em></strong></p><p dir="RTL"><strong>-</strong><strong>National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp; Reporting hotline: 19999</p><p>&middot;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp; Website: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp; Email: saudi.safety@gsk.com<u>&nbsp; </u></p><p>&middot;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p dir="RTL"><strong>THIS IS A MEDICAMENT</strong></p><p dir="RTL">- Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.</p><p dir="RTL">- Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the pharmacist who sold the medicament.</p><p dir="RTL">- The doctor and the pharmacist are experts in medicine, its benefits and risks.</p><p dir="RTL">- Do not by yourself interrupt the period of treatment prescribed for you.</p><p dir="RTL">- Do not repeat the same prescription without consulting your doctor.</p><p dir="RTL">- Keep all medicine out of reach of children.</p><p><strong>Instructions for use</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:
minor-fareast;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_8f0cf12c-67ef-4502-8aac-8defda2f0a79
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:13.0pt;font-family:"Arial",sans-serif;mso-ascii-theme-font:
minor-bidi;mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:
minor-fareast;mso-hansi-theme-font:minor-bidi;mso-bidi-theme-font:minor-bidi;
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>The following information is intended for medical or healthcare professionals only: Upon storage of the suspension, a fine off-white deposit may form.</p><p>Shake the vaccine well before use to form a homogeneous suspension.</p><p>The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine. If two needles of different lengths are provided in the pack, choose the appropriate needle to ensure an intramuscular administration.</p><p><img alt="" width="500" height="340" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><u>Disposal</u></p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><br />&nbsp;</p><p>Bexsero is a Trademark owned by or licensed to the GSK group of companies</p><p>&copy; 2023 GlaxoSmithKline, all rights reserved.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Bexsero looks like and contents of the pack 
Bexsero is a white opalescent suspension.

Bexsero is available in 1-dose pre-filled syringe with or without separate needles, pack sizes of 1 and 10.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA.</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia.</p><p>*member of GlaxoSmithKline group of companies.</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>GSK Vaccines S.r.l.</p><p>Bellaria-Rosia, Sovicille, Siena 53018</p><p>Italy</p><p>Tel: (39) 0577243111&nbsp;&nbsp;&nbsp;&nbsp; Fax: (39) 0577243401</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version number: GDS17

Date of issue: 11 July 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ُعدّ Bexsero لقاحًا للوقاية من المكورات السحائية من المجموعة &nbsp;B.</p><p dir="RTL">ﯾﺤﺘﻮي Bexsero ﻋﻠﻰ أرﺑﻌﺔ ﻣﻜﻮﻧﺎت ﻣﺨﺘﻠﻔﺔ ﻣﻦ ﺳﻄﺢ ﺑﻜﺘﯿﺮﯾﺎ اﻟﻤﺠﻤﻮﻋﺔ B ﻣﻦ <em>اﻟﻨﯿﺴﺮﯾﺔ اﻟﺴﺤﺎﺋﯿﺔ</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾُﻌﻄَﻰ Bexsero ﻟﻸﻓﺮاد ﻣﻦ ﻋﻤﺮ ﺷﮭﺮﯾﻦ ﻓﺄﻛﺒﺮ ﻟﻠﻤﺴﺎﻋﺪة ﻓﻲ اﻟﻮﻗﺎﯾﺔ ﻣﻦ اﻟﻤﺮض اﻟﺬي ﺗﺴﺒﺒﮫ ﺑﻜﺘﯿﺮﯾﺎ اﻟﻤﺠﻤﻮﻋﺔ B.</p><p dir="RTL">ﻣﻦ <em>اﻟﻨﯿﺴﺮﯾﺔ اﻟﺴﺤﺎﺋﯿﺔ</em>. وﯾﻤﻜﻦ أن ﺗﺴﺒﺐ ھﺬه اﻟﺒﻜﺘﯿﺮﯾﺎ اﻟﺘﮭﺎﺑﺎت ﺧﻄﯿﺮة وﻣﮭﺪدة ﻟﻠﺤﯿﺎة أﺣﯿﺎﻧًﺎ، ﻣﺜﻞ اﻟﺘﮭﺎب اﻟﺴﺤﺎﯾﺎ</p><p dir="RTL">(اﻟﺘﮭﺎب ﻏﻼف اﻟﺪﻣﺎغ واﻟﺤﺒﻞ اﻟﺸﻮﻛﻲ) واﻹﻧﺘﺎن (ﺗﺴﻤﻢ اﻟﺪم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻛﻤﺎ ھﻮ اﻟﺤﺎل ﻣﻊ ﺟﻤﯿﻊ اﻟﻠﻘﺎﺣﺎت، ﻗﺪ ﻻ ﯾﻮﻓﺮ Bexsero ﺣﻤﺎﯾﺔ ﻛﺎﻣﻠﺔ ﻟﺒﻌﺾ اﻷﺷﺨﺎص اﻟﺬﯾﻦ ﯾﺘﻢ ﺗﻄﻌﯿﻤﮭﻢ ﺑﮫ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾﺴﺎﻋﺪ Bexsero ﺟﺴﻤﻚ ﻋﻠﻰ ﺗﻜﻮﯾﻦ اﻟﺤﻤﺎﯾﺔ اﻟﺨﺎﺻﺔ ﺑﮫ (اﻷﺟﺴﺎم اﻟﻤﻀﺎدة). وھﺬا ﻣﻦ ﺷﺄﻧﮫ أن ﯾﺤﻤﯿﻚ ﻣﻦ ھﺬا اﻟﻤﺮض.</p><p dir="RTL">ﻻ ﯾﻤﻜﻦ ﻟﻠﻘﺎح أن ﯾﺴﺒﺐ اﻟﻤﺮض اﻟﺬي ﯾﺤﻤﯿﻚ ﻣﻨﮫ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ﯾﺟب ﻋدم إﻋطﺎء </strong><strong>Bexsero</strong><strong> ﻓﻲ اﻟﺣﺎﻻت اﻟﺗﺎﻟﯾﺔ</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><ul><li dir="RTL">ﻓﻲ ﺣﺎﻟﺔ وﺟﻮد ﺣﺴﺎﺳﯿﺔ )ﻓﺮط ﺣﺴﺎﺳﯿﺔ( ﻣﻦ Bexsero، أو أي ﻣﻦ اﻟﻤﻜﻮِّﻧﺎت اﻟﺘﻲ ﯾﺤﺘﻮي ﻋﻠﯿﮭﺎ Bexsero (اﻟﻤﺪرﺟﺔ ﻓﻲ اﻟﻘﺴﻢ ٦). ﻗﺪ ﺗﺸﻤﻞ ﻋﻼﻣﺎت ﺣﺪوث ﺣﺴﺎﺳﯿﺔ ظﮭﻮر اﻟﻄﻔﺢ اﻟﺠﻠﺪي اﻟﻤﺜﯿﺮ ﻟﻠﺤﻜﺔ وﺿﯿﻖ اﻟﺘﻨﻔﺲ وﺗﻮرم اﻟﻮﺟﮫ أو اﻟﻠﺴﺎن.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">اﺳﺘﺸِﺮ طﺒﯿﺒﻚ إذا ﻛﻨﺖ ﺗﻌﺘﻘﺪ أن أﯾًﺎ ﻣﻦ ھﺬه اﻷﻣﻮر ﯾﻨﻄﺒﻖ ﻋﻠﯿﻚ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﯾﻧﺑﻐﻲ ﺗوﺧﻲ اﻟﺣذر ﻋﻧد اﺳﺗﺧدام </strong><strong>Bexsero</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ﻗﺒﻞ ﺗﻨﺎول Bexsero، ﯾﺤﺘﺎج طﺒﯿﺒﻚ إﻟﻰ ﻣﻌﺮﻓﺔ ﻣﺎ ﯾﻠﻲ:</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ ﻋﺪوى ﺷﺪﯾﺪة ﻣﻊ ارﺗﻔﺎع ﻓﻲ درﺟﺔ اﻟﺤﺮارة. ﻓﻲ ﺗﻠﻚ اﻟﺤﺎﻻت، ﻗﺪ ﯾﺘﻢ ﺗﺄﺟﯿﻞ اﻟﺘﻄﻌﯿﻢ ﺑﺎﻟﻠﻘﺎح ﺣﺘﻰ ﯾﺘﻢ اﻟﺸﻔﺎء. ﻣﻦ اﻟﻤﻔﺘﺮض أﻻ ﺗﻤﺜﻞ اﻟﻌﺪوى اﻟﺒﺴﯿﻄﺔ، ﻣﺜﻞ ﻧﺰﻻت اﻟﺒﺮد، ﻣﺸﻜﻠﺔ، وﻟﻜﻦ ﯾﺠﺐ اﺳﺘﺸﺎرة اﻟﻄﺒﯿﺐ أوﻻً.</li><li dir="RTL">إذا ﻛﻨﺖ ﺗﺘﻠﻘﻰ ﻋﻼﺟًﺎ ﯾﻘﻮم ﺑﺈﺣﺼﺎر ھﺬا اﻟﺠﺰء ﻣﻦ اﻟﺠﮭﺎز اﻟﻤﻨﺎﻋﻲ اﻟﻤﻌﺮوف ﺑﺎﺳﻢ اﻟﻤﺘﻤﻢ، ﻣﺜﻞ&nbsp; إﯾﻜﻮﻟﯿﺰوﻣﺎب. ﺣﺘﻰ إذا ﺗﻢ ﺗﻄﻌﯿﻤﻚ ﺑﻠﻘﺎح Bexsero، ﻓﺴﺘﻈﻞ ﻣﻌﺮﺿًﺎ ﺑﻨﺴﺒﺔ ﻣﺘﺰاﯾﺪة ﻟﺨﻄﻮرة اﻹﺻﺎﺑﺔ&nbsp; ﺑﺎﻟﻤﺮض اﻟﻨﺎﺟﻢ ﻋﻦ ﺑﻜﺘﯿﺮﯾﺎ اﻟﻤﺠﻤﻮﻋﺔ B ﻣﻦ <em>اﻟﻨﯿﺴﺮﯾﺔ اﻟﺴﺤﺎﺋﯿﺔ</em>.</li><li dir="RTL">إذا وُ ﻟﺪ طﻔﻠﻚ ﻗﺒﻞ اﻷوان (ﻗﺒﻞ اﻷﺳﺒﻮع ٢٨ ﻣﻦ اﻟﺤﻤﻞ أو ﻓﻲ أﺛﻨﺎﺋﮫ)، وﻻ ﺳﯿﻤﺎ إذا ﻋﺎﻧﻰ ﻣﻦ ﻣﺸﻜﻼت ﺗﻨﻔﺲ، ﯾﺠﺐ إﺧﺒﺎر اﻟﻄﺒﯿﺐ. ﻗﺪ ﯾﻜﻮن اﻟﺘﻮﻗﻒ ﻋﻦ اﻟﺘﻨﻔﺲ أو ﻋﺪم اﻧﺘﻈﺎﻣﮫ ﻟﻔﺘﺮة ﻗﺼﯿﺮة أﻛﺜﺮ ﺷﯿﻮﻋًﺎ ﻓﻲ اﻷﯾﺎم اﻟﺜﻼﺛﺔ اﻷوﻟﻰ ﺑﻌﺪ ﺗﻄﻌﯿﻢ ھﺬا اﻟﻄﻔﻞ اﻟﺮﺿﯿﻊ ﺑﺎﻟﻠﻘﺎح وﻗﺪ ﯾﺤﺘﺎج إﻟﻰ ﻣﺮاﻗﺒﺔ ﺧﺎﺻﺔ.</li><li dir="RTL">ﯾﺠﺐ إﺧﺒﺎر اﻟﻄﺒﯿﺐ أو اﻟﻤﻤﺮﺿﺔ أوﻻً إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ ﺣﺴﺎﺳﯿﺔ ﻣﻦ اﻟﻤﻀﺎد اﻟﺤﯿﻮي ﻛﺎﻧﺎﻣﯿﺴﯿﻦ.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">وﯾﻤﻜﻦ أن ﯾﺤﺪث اﻹﻏﻤﺎء ﺑﻌﺪ، أو ﺣﺘﻰ ﻗﺒﻞ، أي ﺣﻘﻦ ﺑﺎﻹﺑﺮة؛ ﻟﺬﻟﻚ، أﺧﺒﺮ اﻟﻄﺒﯿﺐ أو اﻟﻤﻤﺮﺿﺔ إذا ﻛﻨﺖ ﻗﺪ ﺗﻌﺮﺿﺖ ﻟﻺﻏﻤﺎء ﺑﺴﺒﺐ اﻟﺤﻘﻦ ﻓﻲ اﻟﺴﺎﺑﻖ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻟﻢ ﺗﺜﺒﺖ ﺳﻼﻣﺔ وﻓﻌﺎﻟﯿﺔ Bexsero ﺑﺎﻟﻨﺴﺒﺔ ﻟﻸﻓﺮاد اﻟﺬﯾﻦ ﺗﺘﺠﺎوز أﻋﻤﺎرھﻢ ٥٠ ﻋﺎﻣًﺎ. ﺗﺘﻮﻓﺮ ﺑﯿﺎﻧﺎت ﻣﺤﺪودة ﺣﻮل اﺳﺘﺨﺪام Bexsero ﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﻤﺮﺿﻰ اﻟﻤﺼﺎﺑﯿﻦ ﺑﺤﺎﻻت ﻣﺮﺿﯿﺔ ﻣﺰﻣﻨﺔ أو ﺿﻌﻒ اﻟﻤﻨﺎﻋﺔ. ﻗﺪ ﻻ ﯾﺴﺘﻔﯿﺪ اﻷﺷﺨﺎص اﻟﺬﯾﻦ ﯾﻌﺎﻧﻮن ﻣﻦ ﺿﻌﻒ ﻓﻲ ﺟﮭﺎز اﻟﻤﻨﺎﻋﺔ، ﺑﺴﺒﺐ اﻹﺻﺎﺑﺔ ﺑﻔﯿﺮوس ﻧﻘﺺ اﻟﻤﻨﺎﻋﺔ اﻟﺒﺸﺮﯾﺔ أو ﺑﺴﺒﺐ اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺜﺒﻂ اﻟﺠﮭﺎز</p><p dir="RTL">اﻟﻤﻨﺎﻋﻲ، ﻋﻠﻰ ﺳﺒﯿﻞ اﻟﻤﺜﺎل، اﺳﺘﻔﺎدة ﻛﺎﻣﻠﺔ ﻣﻦ ﻟﻘﺎحBexsero &nbsp;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اﺳﺗﺧدام أدوﯾﺔ أو ﻟﻘﺎﺣﺎت أﺧرى</strong></p><p dir="RTL">أﺧﺒﺮ اﻟﻄﺒﯿﺐ أو اﻟﻤﻤﺮﺿﺔ إذا ﻛﻨﺖ ﺗﺘﻨﺎول ﺣﺎﻟﯿًﺎ، أو إذا ﻛﻨﺖ ﻗﺪ ﺗﻨﺎوﻟﺖ ﻣﺆﺧﺮً ا أي أدوﯾﺔ أﺧﺮى، ﺑﻤﺎ ﻓﻲ ذﻟﻚ اﻷدوﯾﺔ اﻟﺘﻲ ﯾﺘﻢ اﻟﺤﺼﻮل ﻋﻠﯿﮭﺎ دون وﺻﻔﺔ طﺒﯿﺔ، أو إذا ﻛﻨﺖ ﻗﺪ أﺧﺬت ﻣﺆﺧﺮً ا أي ﻟﻘﺎح آﺧﺮ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾﻤﻜﻦ إﻋﻄﺎء Bexsero ﻓﻲ ﻧﻔﺲ اﻟﻮﻗﺖ ﻣﻊ أي ﻣﻦ ﻣﻜﻮﻧﺎت اﻟﻠﻘﺎﺣﺎت اﻟﺘﺎﻟﯿﺔ: ﻟﻘﺎح اﻟﺨﻨﺎق واﻟﺘﯿﺘﺎﻧﻮس واﻟﺴﻌﺎل اﻟﺪﯾﻜﻲ (اﻟﺸﺎھﻮق) <em>وﻟﻘﺎح اﻹﻧﻔﻠﻮﻧﺰا اﻟﻤﺴﺘﺪﻣﯿﺔ</em> ﻣﻦ اﻟﻨﻮع B وﻟﻘﺎح ﺷﻠﻞ اﻷطﻔﺎل وﻟﻘﺎح اﻟﺘﮭﺎب اﻟﻜﺒﺪ اﻟﻮﺑﺎﺋﻲ B وﻟﻘﺎح اﻟﻤﻜﻮرات اﻟﺮﺋﻮﯾﺔ وﻟﻘﺎﺣﺎت اﻟﺤﺼﺒﺔ واﻟﻨﻜﺎف واﻟﺤﺼﺒﺔ اﻷﻟﻤﺎﻧﯿﺔ وﻟﻘﺎح ﺟﺪري اﻟﻤﺎء وﻟﻘﺎﺣﺎت اﻟﻤﻜﻮرات اﻟﺴﺤﺎﺋﯿﺔ A وC وW وY. ﺳﯿﺘﻢ اﺳﺘﺨﺪام ﻣﻮﺿﻊ ﺣﻘﻦ ﻣﺨﺘﻠﻒ ﻟﻜﻞ ﻧﻮع ﻟﻘﺎح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻗﺪ ﯾﻄﻠﺐ اﻟﻄﺒﯿﺐ أو اﻟﻤﻤﺮﺿﺔ ﻣﻨﻚ إﻋﻄﺎء طﻔﻠﻚ أدوﯾﺔ ﺗﺨﻔﺾ اﻟﺤﻤﻰ ﻓﻲ وﻗﺖ إﻋﻄﺎء Bexsero وﺑﻌﺪه. وﻣﻦ ﺷﺄن ذﻟﻚ أن ﯾﺴﺎﻋﺪ ﻓﻲ ﺗﻘﻠﯿﻞ ﺑﻌﺾ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ ﻟﻠﻘﺎحBexsero .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل واﻟرﺿﺎﻋﺔ اﻟطﺑﯾﻌﯾﺔ </strong></p><p dir="RTL">ﯾﺠﺐ اﺳﺘﺸﺎرة اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ ﻗﺒﻞ ﺗﻨﺎول أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اﻟﻘﯾﺎدة واﺳﺗﺧدام اﻵﻻت</strong></p><p dir="RTL">ﻻ ﯾﺆﺛﺮ Bexsero ﻋﻠﻰ اﻟﻘﺪرة ﻋﻠﻰ اﻟﻘﯿﺎدة واﺳﺘﺨﺪام اﻵﻻت أو ﯾﺆﺛﺮ ﺗﺄﺛﯿﺮً ا ﻻ ﯾُﺬﻛَﺮ ﻋﻠﯿﮭﻤﺎ. وﻟﻜﻦ ﻗﺪ ﺗﺆﺛﺮ ﺑﻌﺾ اﻵﺛﺎر اﻟﻮاردة ﺿﻤﻦ اﻟﻘﺴﻢ ٤ &quot;اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺤﺘﻤﻠﺔ&quot; ﺗﺄﺛﯿﺮً ا ﻣﺆﻗﺘًﺎ ﻋﻠﻰ اﻟﻘﺪرة ﻋﻠﻰ اﻟﻘﯿﺎدة أو اﺳﺘﺨﺪام اﻵﻻت.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ﻛﯾﻔﯾﺔ إﻋطﺎء ﻟﻘﺎح </strong><strong>Bexsero</strong></p><p dir="RTL">ﯾﺘﻢ إﻋﻄﺎؤك Bexsero (٠٫٥ ﻣﻞ) ﺑﻮاﺳﻄﺔ اﻟﻄﺒﯿﺐ أو اﻟﻤﻤﺮﺿﺔ. وﺳﯿﺘﻢ ﺣﻘﻨﮫ ﻓﻲ اﻟﻌﻀﻼت، ﻋﺎدةً ﻓﻲ اﻟﻔﺨﺬ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻠﺮﺿﻊ أو أﻋﻠﻰ اﻟﺬراع ﺑﺎﻟﻨﺴﺒﺔ ﻟﻸطﻔﺎل واﻟﻤﺮاھﻘﯿﻦ واﻟﺒﺎﻟﻐﯿﻦ. ﻣﻦ اﻟﻤﮭﻢ اﺗﺒﺎع ﺗﻌﻠﯿﻤﺎت اﻟﻄﺒﯿﺐ أو اﻟﻤﻤﺮﺿﺔ ﺣﺘﻰ ﺗﻜﻤﻞ اﻟﻤﺴﺎر اﻟﻌﻼﺟﻲ ﻟﻠﺤُﻘَﻦ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اﻟﺮﺿﻊ ﻣﻦ ﻋﻤﺮ ﺷﮭﺮﯾﻦ إﻟﻰ ٥ أﺷﮭﺮ ﻓﻲ وﻗﺖ اﻟﺠﺮﻋﺔ اﻷوﻟﻰ</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾﻨﺒﻐﻲ أن ﯾﻜﻤﻞ طﻔﻠﻚ ﻣﺴﺎرً ا ﻋﻼﺟﯿًﺎ أوﻟﯿًﺎ ﯾﺸﻤﻞ ﺛﻼث ﺣُﻘَﻦ ﺗﺘﺒﻌﮭﺎ ﺣﻘﻨﺔ إﺿﺎﻓﯿﺔ (ﻣﻌﺰزة).</p><ul><li dir="RTL">وﯾﻨﺒﻐﻲ أﻻ ﯾﻘﻞ اﻟﻔﺎﺻﻞ اﻟﺰﻣﻨﻲ ﺑﯿﻦ اﻟﺤُﻘَﻦ ﻋﻦ ﺷﮭﺮﯾﻦ إذا ﻛﺎن ﯾﺘﻢ إﻋﻄﺎء ﺟﺮﻋﺘﯿﻦ أوﻟﯿﺘﯿﻦ أو ﻋﻦ ﺷﮭﺮ واﺣﺪ إذا ﻛﺎن ﯾﺘﻢ إﻋﻄﺎء ﺛﻼث ﺟﺮﻋﺎت أوﻟﯿﺔ.</li><li dir="RTL">وﯾﺘﻢ إﻋﻄﺎء اﻟﺤﻘﻨﺔ اﻟﻤﻌﺰزة ﻓﻲ اﻟﺴﻨﺔ اﻟﺜﺎﻧﯿﺔ ﻣﻦ اﻟﻌﻤﺮ ﺑﻌﺪ ﻓﺎﺻﻞ زﻣﻨﻲ ﻻ ﯾﻘﻞ ﻋﻦ ٦ أﺷﮭﺮ ﻣﻦ آﺧر ﺣﻘﻨﺔ ﻓﻲ اﻟﻤﺴﺎر اﻟﻌﻼﺟﻲ اﻷوﻟﻲ.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اﻟﺮﺿﻊ ﻣﻦ ﻋﻤﺮ ٦ أﺷﮭﺮ إﻟﻰ ١١ ﺷﮭﺮاً ﻓﻲ وﻗﺖ اﻟﺠﺮﻋﺔ اﻷوﻟﻰ</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾﻨﺒﻐﻲ أن ﯾﺘﻠﻘﻰ اﻟﺮﺿﻊ اﻟﺬﯾﻦ ﺗﺘﺮاوح أﻋﻤﺎرھﻢ ﺑﯿﻦ ٦ أﺷﮭﺮ و١١ ﺷﮭﺮً ا ﺣﻘﻨﺘﯿﻦ ﻣﻦ اﻟﻠﻘﺎح ﺗﺘﺒﻌﮭﻤﺎ ﺣﻘﻨﺔ إﺿﺎﻓﯿﺔ (ﻣﻌﺰزة).</p><ul><li dir="RTL">وﯾﻨﺒﻐﻲ أﻻ ﯾﻘﻞ اﻟﻔﺎﺻﻞ اﻟﺰﻣﻨﻲ ﺑﯿﻦ ﻛﻞ ﺣﻘﻨﺔ واﻷﺧﺮى ﻋﻦ ﺷﮭﺮﯾﻦ.</li><li dir="RTL">وﯾﺘﻢ إﻋﻄﺎء اﻟﺤﻘﻨﺔ اﻟﻤﻌﺰزة ﻓﻲ اﻟﺴﻨﺔ اﻟﺜﺎﻧﯿﺔ ﻣﻦ اﻟﻌﻤﺮ ﺑﻌﺪ ﻓﺎﺻﻞ زﻣﻨﻲ ﻻ ﯾﻘﻞ ﻋﻦ ﺷﮭﺮﯾﻦ ﻣﻦ اﻟﺤﻘﻨﺔ اﻟﺜﺎﻧﯿﺔ.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>اﻷطﻔﺎل ﻣﻦ ﻋﻤﺮ ١٢ إﻟﻰ ٢٣ ﺷﮭﺮاً ﻓﻲ وﻗﺖ اﻟﺠﺮﻋﺔ اﻷوﻟﻰ</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾﻨﺒﻐﻲ أن ﯾﺘﻠﻘﻰ اﻷطﻔﺎل اﻟﺬﯾﻦ ﺗﺘﺮاوح أﻋﻤﺎرھﻢ ﺑﯿﻦ ١٢ و٢٣ ﺷﮭﺮً ا ﺣﻘﻨﺘﯿﻦ ﻣﻦ اﻟﻠﻘﺎح ﺗﺘﺒﻌﮭﻤﺎ ﺣﻘﻨﺔ إﺿﺎﻓﯿﺔ (ﻣﻌﺰزة).</p><ul><li dir="RTL">وﯾﻨﺒﻐﻲ أﻻ ﯾﻘﻞ اﻟﻔﺎﺻﻞ اﻟﺰﻣﻨﻲ ﺑﯿﻦ ﻛﻞ ﺣﻘﻨﺔ واﻷﺧﺮى ﻋﻦ ﺷﮭﺮﯾﻦ.</li><li dir="RTL">وﯾﺘﻢ إﻋﻄﺎء اﻟﺤﻘﻨﺔ اﻟﻤﻌﺰزة ﺑﻌﺪ ﻓﺎﺻﻞ زﻣﻨﻲ ﯾﺘﺮاوح ﺑﯿﻦ ١٢ و٢٣ ﺷﮭﺮً ا ﻣﻦ اﻟﺤﻘﻨﺔ اﻟﺜﺎﻧﯿﺔ.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اﻷطﻔﺎل ﻣﻦ ﻋﻤﺮ ﻋﺎﻣﯿﻦ إﻟﻰ ١٠ أﻋﻮام ﻓﻲ وﻗﺖ اﻟﺠﺮﻋﺔ اﻷوﻟﻰ</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾﻨﺒﻐﻲ أن ﯾﺘﻠﻘﻰ طﻔﻠﻚ ﺣﻘﻨﺘﯿﻦ ﻣﻦ اﻟﻠﻘﺎح ﺗﻔﺼﻞ ﺑﯿﻨﮭﻤﺎ ﻓﺘﺮة زﻣﻨﯿﺔ ﻻ ﺗﻘﻞ ﻋﻦ ﺷﮭﺮ واﺣﺪ. ﯾﻤﻜﻦ أن ﯾﺘﻠﻘﻰ طﻔﻠﻚ ﺣﻘﻨﺔ إﺿﺎﻓﯿﺔ (ﻣﻌﺰزة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اﻟﻤﺮاھﻘﻮن واﻟﺒﺎﻟﻐﻮن ﻣﻦ ﻋﻤﺮ ١١ ﻋﺎﻣﺎً ﻓﻲ وﻗﺖ اﻟﺠﺮﻋﺔ اﻷوﻟﻰ</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾﻨﺒﻐﻲ أن ﺗﺘﻠﻘﻰ ﺣﻘﻨﺘﯿﻦ ﻣﻦ اﻟﻠﻘﺎح ﺗﻔﺼﻞ ﺑﯿﻨﮭﻤﺎ ﻓﺘﺮة زﻣﻨﯿﺔ ﻻ ﺗﻘﻞ ﻋﻦ ﺷﮭﺮ واﺣﺪ. ﯾﻤﻜﻦ أن ﺗﺘﻠﻘﻰ ﺣﻘﻨﺔ إﺿﺎﻓﯿﺔ (ﻣﻌﺰزة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اﻟﺒﺎﻟﻐﻮن اﻟﺬﯾﻦ ﺗﺰﯾﺪ أﻋﻤﺎرھﻢ ﻋﻦ ٥٠ ﻋﺎﻣﺎً</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻟﻢ ﺗﺜﺒﺖ ﺳﻼﻣﺔ وﻓﻌﺎﻟﯿﺔ Bexsero ﺑﺎﻟﻨﺴﺒﺔ ﻟﻸﻓﺮاد اﻟﺬﯾﻦ ﺗﺘﺠﺎوز أﻋﻤﺎرھﻢ ٥٠ ﻋﺎﻣ ًﺎ. اﺳﺘﺸﺮ طﺒﯿﺒﻚ ﻋﻤﺎ إذا ﻛﺎن ﻣﻦ اﻟﻤﻔﯿﺪ ﻟﻚ ﺗﻨﺎول Bexsero أم ﻻ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ﻛﺎﻧﺖ ﻟﺪﯾﻚ أي اﺳﺘﻔﺴﺎرات أﺧﺮى ﺣﻮل Bexsero، ﻓﺎﺳﺄل اﻟﻄﺒﯿﺐ أو اﻟﻤﻤﺮﺿﺔ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﻓﻲ ﺣﺎﻟﺔ ﺗﻔوﯾت ﺟرﻋﺔ ﻣن </strong><strong>Bexsero</strong><strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إذا ﻓﺎﺗﺘﻚ ﺣﻘﻨﺔ ﻣﺠﺪوﻟﺔ، ﻓﻤﻦ اﻟﻤﮭﻢ أن ﺗﻘﻮم ﺑﺘﺤﺪﯾﺪ ﻣﻮﻋﺪ آﺧﺮ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﺗﺄﻛّﺪ ﻣﻦ اﺳﺘﻜﻤﺎﻟﻚ ﻟﺒﺮﻧﺎﻣﺞ اﻟﺘﻄﻌﯿﻢ ﺑﺎﻟﻜﺎﻣﻞ. وإذا ﻟﻢ ﯾﺤﺪث ذﻟﻚ، ﻓﻘﺪ ﻻ ﺗﻜﻮن ﻣﺤﻤﯿًﺎ ﺣﻤﺎﯾﺔ ﻛﺎﻣﻠﺔ ﻣﻦ اﻷﻣﺮاض.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﻣﺜﻞ ﺟﻤﯿﻊ اﻷدوﯾﺔ، ﯾﻤﻜﻦ أن ﯾﺘﺴﺒﺐ Bexsero ﻓﻲ آﺛﺎر ﺟﺎﻧﺒﯿﺔ، إﻻ أﻧﮭﺎ ﻻ ﺗﺼﯿﺐ اﻟﺠﻤﯿﻊ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>ﺟﻤﯿﻊ اﻟﻔﺌﺎت اﻟﻌﻤﺮﯾﺔ</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻋﻨﺪ إﻋﻄﺎء Bexsero ﻟﻚ أو طﻔﻠﻚ، ﺗﻜﻮن اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺸﺎﺋﻌﺔ ﺟﺪًا (اﻟﺘﻲ ﯾﻤﻜﻦ أن ﺗﺼﯿﺐ أﻛﺜﺮ ﻣﻦ ﺷﺨﺺ واﺣﺪ</p><p dir="RTL">ﺑﯿﻦ ﻛﻞ ١٠ أﺷﺨﺎص) واﻟﺘﻲ ﯾﻤﻜﻦ أن ﺗﺼﺎب ﺑﮭﺎ أﻧﺖ أو طﻔﻠﻚ (ﺗﻢ اﻹﺑﻼغ ﻋﻨﮭﺎ ﺑﯿﻦ ﻛﻞ اﻟﻔﺌﺎت اﻟﻌﻤﺮﯾﺔ):</p><ul><li dir="RTL">أﻟﻢ/ﺗﻮﺟّﻊ ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ، اﺣﻤﺮار اﻟﺠﻠﺪ ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ، ﺗﻮرم اﻟﺠﻠﺪ ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ، ﺗﯿﺒﺲ اﻟﺠﻠﺪ ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻗﺪ ﺗﺤﺪث ﻛﺬﻟﻚ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﺎﻟﯿﺔ ﺑﻌﺪ ﺗﻨﺎول ھﺬا اﻟﻠﻘﺎح:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اﻟﺮﺿﻊ واﻷطﻔﺎل (ﺣﺘﻰ ١٠ أﻋﻮام)</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﺷﺎﺋﻌﺔ ﺟﺪًا</strong> (ﻗﺪ ﺗﺼﯿﺐ أﻛﺜﺮ ﻣﻦ ﺷﺨﺺ واﺣﺪ ﻣﻦ ﻛﻞ ١٠ أﺷﺨﺎص):</p><ul><li dir="RTL">حمى (&ge; 38 درﺟﺔ ﻣﺌﻮﯾﺔ)</li><li dir="RTL">ﻓﻘﺪان ﺷﮭﯿﺔ</li><li dir="RTL">ﺗﻮﺟّﻊ ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ (ﺑﻤﺎ ﻓﻲ ذﻟﻚ ﺗﻮﺟّﻊ ﺷﺪﯾﺪ ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ ﯾﺆدي إﻟﻰ اﻟﺒﻜﺎء ﻋﻨﺪ ﺗﺤﺮك اﻟﻄﺮف اﻟﻤﺤﻘﻮن)</li><li dir="RTL">أﻟﻢ ﻓﻲ اﻟﻤﻔﺎﺻﻞ</li><li dir="RTL">طﻔﺢ ﺟﻠﺪي (ﺑﯿﻦ اﻷطﻔﺎل ﻣﻦ ﻋﻤﺮ ١٢ إﻟﻰ ٢٣ ﺷﮭراً) (ﻏﯿﺮ ﺷﺎﺋﻊ ﺑﻌﺪ اﻟﺤﻘﻨﺔ اﻟﻤﻌﺰزة)</li><li dir="RTL">ﻧﻌﺎس</li><li dir="RTL">ﺷﻌﻮر ﺑﺴﺮﻋﺔ اﻻﻧﻔﻌﺎل</li><li dir="RTL">ﺑﻜﺎء ﻏﯿﺮ ﻋﺎدي</li><li dir="RTL">ﻗﻲء (ﻏﯿﺮ ﺷﺎﺋﻊ ﺑﻌﺪ اﻟﺤﻘﻨﺔ اﻟﻤﻌﺰزة)</li><li dir="RTL">إﺳﮭﺎل</li><li dir="RTL">ﺻﺪاع</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آﺛﺎر ﺟﺎﻧﺒﯿﺔ ﺷﺎﺋﻌﺔ</strong> (ﻗﺪ ﺗﺼﯿﺐ ﺣﺘﻰ ﺷﺨﺺ واﺣﺪ ﻣﻦ ﺑﯿﻦ ﻛﻞ ١٠ أﺷﺨﺎص):</p><ul><li dir="RTL">طﻔﺢ ﺟﻠﺪي (اﻟﺮﺿﻊ واﻷطﻔﺎل ﻣﻦ ﻋﻤﺮ ﻋﺎﻣﯿﻦ ﺣﺘﻰ ١٠ أﻋﻮام)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﻏﯿﺮ ﺷﺎﺋﻌﺔ</strong> (ﻗﺪ ﺗﺼﯿﺐ ﺣﺘﻰ ﺷﺨﺺ واﺣﺪ ﻣﻦ ﺑﯿﻦ ﻛﻞ ١٠٠ ﺷﺨﺺ):</p><ul><li dir="RTL">ﺣﻤﻰ ﺷﺪﯾﺪة (&ge;٤٠ درﺟﺔ ﻣﺌﻮﯾﺔ)</li><li dir="RTL">ﻧﻮﺑﺎت (ﺑﻤﺎ ﻓﻲ ذﻟﻚ ﻧﻮﺑﺎت ﺣﻤﻮﯾﺔ)</li><li dir="RTL">ﺟﻔﺎف اﻟﺠﻠﺪ</li><li dir="RTL">ﺷﺤﻮب (ﻧﺎدر ﺑﻌﺪ اﻟﺤﻘﻨﺔ اﻟﻤﻌﺰزة)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آﺛﺎر ﺟﺎﻧﺒﯿﺔ ﻧﺎدرة</strong> (ﻗﺪ ﺗﺼﯿﺐ ﺣﺘﻰ ﺷﺨﺺ واﺣﺪ ﻣﻦ ﺑﯿﻦ ﻛﻞ ١٠٠٠ ﺷﺨﺺ):</p><ul><li dir="RTL">ﻣﺮض ﻛﺎواﺳﺎﻛﻲ اﻟﺬي ﻗﺪ ﯾﺸﻤﻞ أﻋﺮاﺿًﺎ ﻣﺜﻞ اﻟﺤﻤﻰ اﻟﺘﻲ ﺗﺴﺘﻤﺮ ﻷﻛﺜﺮ ﻣﻦ ﺧﻤﺴﺔ أﯾﺎم، ﻣﻘﺘﺮﻧﺔ ﺑﻄﻔﺢ ﺟﻠﺪي ﻋﻠﻰ ﺟﺬع اﻟﺠﺴﻢ ﯾﺘﺒﻌﮭﺎ ﻓﻲ ﺑﻌﺾ اﻷﺣﯿﺎن ﺗﻘﺸﯿﺮ ﻓﻲ اﻟﺠﻠﺪ ﻋﻠﻰ اﻟﯿﺪﯾﻦ واﻷﺻﺎﺑﻊ وﺗﻮرم اﻟﻐﺪد ﻓﻲ اﻟﺮﻗﺒﺔ واﺣﻤﺮار اﻟﻌﯿﻨﯿﻦ واﻟﺸﻔﺘﯿﻦ واﻟﺤﻠﻖ واﻟﻠﺴﺎن</li><li dir="RTL">اﻟﻄﻔﺢ اﻟﻤﺜﯿﺮ ﻟﻠﺤﻜﺔ، اﻟﻄﻔﺢ اﻟﺠﻠﺪي</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اﻟﻤﺮاھﻘﻮن (ﻣﻦ ﻋﻤﺮ١١</em><em> </em><em>ﺳﻨﺔ) واﻟﺒﺎﻟﻐﻮن</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﺷﺎﺋﻌﺔ ﺟﺪًا</strong> (ﻗﺪ ﺗﺼﯿﺐ أﻛﺜﺮ ﻣﻦ ﺷﺨﺺ واﺣﺪ ﻣﻦ ﻛﻞ ١٠ أﺷﺨﺎص):</p><ul><li dir="RTL">أﻟﻢ ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ ﯾﺆدي إﻟﻰ ﻋﺠﺰ ﻋﻦ أداء اﻷﻧﺸﻄﺔ اﻟﯿﻮﻣﯿﺔ اﻟﻌﺎدﯾﺔ</li><li dir="RTL">أﻟﻢ ﻓﻲ اﻟﻌﻀﻼت واﻟﻤﻔﺎﺻﻞ</li><li dir="RTL">ﻏﺜﯿﺎن</li><li dir="RTL">ﺷﻌﻮر ﻋﺎم ﺑﻌﺪم اﻟﺮاﺣﺔ</li><li dir="RTL">ﺻﺪاع</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><em>ﺑﯿﺎﻧﺎت ﺑﻌﺪ اﻟﺘﺪاول</em></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﺗﺸﻤﻞ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﻲ ﺗﻢ اﻹﺑﻼغ ﻋﻨﮭﺎ أﺛﻨﺎء اﻟﺘﺪاول ﻣﺎ ﯾﻠﻲ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الغدد الليمفاوية</p><ul><li dir="RTL">ﺗﻔﺎﻋﻼت ﺣﺴﺎﺳﯿﺔ ﻗﺪ ﺗﺸﻤﻞ اﻟﺘﻮرم اﻟﺤﺎد ﻓﻲ اﻟﺸﻔﺘﯿﻦ واﻟﻔﻢ واﻟﺤﻠﻖ (واﻟﺬي ﻗﺪ ﯾﺴﺒﺐ ﺻﻌﻮﺑﺔ ﻓﻲ اﻟﺒﻠﻊ) وﺻﻌﻮﺑﺔ اﻟﺘﻨﻔﺲ ﻣﻊ أزﯾﺰ ﺻﺪري أو ﺳﻌﺎل واﻟﻄﻔﺢ اﻟﺠﻠﺪي وﻓﻘﺪان اﻟﻮﻋﻲ واﻧﺨﻔﺎض ﺿﻐﻂ اﻟﺪم اﻟﺸﺪﯾﺪ</li><li dir="RTL">إﻏﻤﺎء (ظﮭﻮر ﻣﻔﺎﺟﺊ ﻟﻨﻘﺺ اﻟﺘﻮﺗﺮ اﻟﻌﻀﻠﻲ) واﻧﺨﻔﺎض اﻻﺳﺘﺠﺎﺑﺔ ﻋﻦ اﻟﻤﺴﺘﻮى اﻟﻤﻌﺘﺎد أو ﻧﻘﺺ اﻟﻮﻋﻲ واﻟﺸﺤﻮب أو ﺗﻐﯿﺮ ﻟﻮن اﻟﺠﻠﺪ إﻟﻰ اﻷزرق ﺑﯿﻦ اﻷطﻔﺎل اﻟﺼﻐﺎر أو اﻟﺸﻌﻮر ﺑﺎﻹﻏﻤﺎء أو اﻹﻏﻤﺎء</li><li dir="RTL">طفح جلدي (ﺑﯿﻦ اﻟﻤﺮاھﻘﯿﻦ ﻣﻦ ﻋﻤﺮ ١١ ﻋﺎﻣًﺎ واﻟﺒﺎﻟﻐﯿﻦ)</li><li dir="RTL">ﺣﻤﻰ (ﺑﯿﻦ اﻟﻤﺮاھﻘﯿﻦ ﻣﻦ ﻋﻤﺮ ١١ ﻋﺎﻣًﺎ واﻟﺒﺎﻟﻐﯿﻦ)، وﺗﻔﺎﻋﻼت ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ ﻣﺜﻞ ﺗﻮرم ﻋﻠﻰ ﻧﻄﺎق واﺳﻊ ﻓﻲ اﻟﻄﺮف اﻟﻤﺤﻘﻮن، وﺑﺜﻮر ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ أو ﺣﻮﻟﮫ، وﻛﺘﻠﺔ ﺻﻠﺒﺔ ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ (ﯾﻤﻜﻦ أن ﺗﺴﺘﻤﺮ ﻷﻛﺜﺮ ﻣﻦ ﺷﮭﺮ)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">ﻓﻲ ﺣﺎﻟﺔ ﺗﻔﺎﻗﻢ أي ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ أو إذا ﻻﺣﻈﺖ ظﮭﻮر أي آﺛﺎر ﺟﺎﻧﺒﯿﺔ ﻏﯿﺮ ﻣﺬﻛﻮرة ﻓﻲ ھﺬه اﻟﻨﺸﺮة، ﯾُﺮﺟﻰ إﺑﻼغ اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﯾﺠﺐ ﺣﻔﻆ اﻟﺪواء ﺑﻌﯿﺪًا ﻋﻦ ﻣﺮأى وﻣﺘﻨﺎول اﻷطﻔﺎل. ﯾُﺤﻔﻆ ﻓﻲ اﻟﺜﻼﺟﺔ (ﺑﯿﻦ درﺟﺘﯿﻦ ﻣﺌﻮﯾﺘﯿﻦ و٨ درﺟﺎت ﻣﺌﻮﯾﺔ).</p><p dir="RTL">ﯾﺠﺐ ﻋﺪم ﺗﺠﻤﯿﺪه.</p><p dir="RTL">ﯾُﺤﻔﻆ ﻓﻲ اﻟﻌﺒﻮة اﻷﺻﻠﯿﺔ ﻟﺤﻤﺎﯾﺘﮫ ﻣﻦ اﻟﻀﻮء.</p><p dir="RTL">ﻻ ﺗﺴﺘﺨﺪم اﻟﺪواء ﺑﻌﺪ ﺗﺎرﯾﺦ اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ اﻟﻤﺪوﱠ ن ﻋﻠﻰ اﻟﻌﺒﻮة. ﯾﺸﯿﺮ ﺗﺎرﯾﺦ اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ إﻟﻰ اﻟﯿﻮم اﻷﺧﯿﺮ ﻣﻦ اﻟﺸﮭﺮ اﻟﻤﺬﻛﻮر.</p><p dir="RTL">ﻻ ﺗﺘﺨﻠﺺ ﻣﻦ أي أدوﯾﺔ ﺑﺈﻟﻘﺎﺋﮭﺎ ﻓﻲ ﻣﯿﺎه اﻟﺼﺮف اﻟﺼﺤﻲ أو اﻟﻨﻔﺎﯾﺎت اﻟﻤﻨﺰﻟﯿﺔ. اﺳﺘﺸﺮ اﻟﺼﯿﺪﻟﻲ ﻋﻦ ﻛﯿﻔﯿﺔ اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ اﻟﺘﻲ ﻟﻢ ﺗﻌﺪ ﺗﺴﺘﻌﻤﻠﮭﺎ. ﻓﮭﺬه اﻹﺟﺮاءات ﻣﻦ ﺷﺄﻧﮭﺎ أن ﺗﺤﺎﻓﻆ ﻋﻠﻰ اﻟﺒﯿﺌﺔ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ﻣﻛوّﻧﺎت </strong><strong>Bexsero</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">ﺗﺤﺘﻮي اﻟﺠﺮﻋﺔ اﻟﻮاﺣﺪة (٠٫٥ ﻣﻞ) ﻋﻠﻰ:</p><p dir="RTL">&nbsp;</p><p dir="RTL">اﻟﻤﻮاد اﻟﻔﻌﱠﺎﻟﺔ ھﻲ:</p><p dir="RTL">اﻟﺒﺮوﺗﯿﻦ اﻻﻧﺪﻣﺎﺟﻲ ﻣﻌﺎد اﻟﺘﺮﻛﯿﺐ NHBA ﻟﻠﻤﺠﻤﻮﻋﺔ B&nbsp; ﻣﻦ <em>اﻟﻨﯿﺴﺮﯾﺔ اﻟﺴﺤﺎﺋﯿﺔ</em>&shy;&shy;<sup>3،2،1</sup><sup> </sup><sup>&nbsp;</sup>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥٠ ﻣﯿﻜﺮوﺟﺮام</p><p dir="RTL">اﻟﺒﺮوﺗﯿﻦ ﻣﻌﺎد اﻟﺘﺮﻛﯿﺐ NadA ﻟﻠﻤﺠﻤﻮﻋﺔ B ﻣﻦ <em>اﻟﻨﯿﺴﺮﯾﺔ اﻟﺴﺤﺎﺋﯿﺔ</em>&shy;&shy;<sup>3،2،1</sup><sup> </sup><sup>&nbsp;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥٠ ﻣﯿﻜﺮوﺟﺮام</p><p dir="RTL">اﻟﺒﺮوﺗﯿﻦ اﻻﻧﺪﻣﺎﺟﻲ ﻣﻌﺎد اﻟﺘﺮﻛﯿﺐ fHbp ﻟﻠﻤﺠﻤﻮﻋﺔ B ﻣﻦ <em>اﻟﻨﯿﺴﺮﯾﺔ اﻟﺴﺤﺎﺋﯿﺔ</em>&shy;&shy;<sup>3،2،1</sup><sup> </sup><sup>&nbsp;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٥٠ ﻣﯿﻜﺮوﺟﺮام</p><p dir="RTL">ﺣﻮﯾﺼﻼت اﻟﻐﺸﺎء اﻟﺨﺎرﺟﻲ (OMV) ﻣﻦ ﺳﻼﻟﺔ اﻟﻤﺠﻤﻮﻋﺔ B <em>ﻣﻦ اﻟﻨﯿﺴﺮﯾﺔ اﻟﺴﺤﺎﺋﯿﺔ</em></p><p dir="RTL">NZ98/254، يتم قياسها كمقدار إجمالي البروتين الذي يحتوي على PorA P1.4<sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 ﻣﯿﻜﺮوﺟﺮام</p><p dir="RTL">ﺗﻢ اﻹﻧﺘﺎج ﻓﻲ ﺧﻼﯾﺎ إﺷﺮﯾﻜﯿﺔ ﻗﻮﻟﻮﻧﯿﺔ ﻋﻦ طﺮﯾﻖ ﺗﻜﻨﻮﻟﻮﺟﯿﺎ اﻟﺤﻤﺾ اﻟﻨﻮوي ﻣُﻌﺎد اﻟﺘﺮﻛﯿﺐ</p><p dir="RTL">ﻣُﻤْﺘَﺰّ ﻓﻲ ھﯿﺪروﻛﺴﯿﺪ اﻷﻟﻮﻣﻨﯿﻮم (٠٫٥ ﻣﻠﺠﻢ Al)</p><p dir="RTL">NHBA (اﻟﻤﺴﺘﻀﺪ اﻟﻨﯿﺴﺮي راﺑﻂ اﻟﮭﯿﺒﺎرﯾﻦ)، وNadA اﻻﻟﺘﺼﺎق (اﻟﻨﺴﯿﺮي A)، وfHbp (اﻟﺒﺮوﺗﯿﻦ راﺑﻂ اﻟﻌﺎﻣﻞ H)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>اﻟﻤﻜﻮﻧّﺎت اﻷﺧﺮى ھﻲ: </em></p><p dir="RTL">ﻛﻠﻮرﯾﺪ اﻟﺼﻮدﯾﻮم وھﺴﺘﯿﺪﯾﻦ وﺳﻜﺮوز وﻣﺎء ﻟﻠﺤﻘﻦ</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﺷﻛل </strong><strong>Bexsero</strong><strong> وﻣﺣﺗوﯾﺎت اﻟﻌﺑوة</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">Bexsero هو مستعلق أبيض حليبي اللون.</p><p dir="RTL">يتوفر Bexsero في حقنة مملوءة مسبقًا بجرعة واحدة مع أو بدون إبر منفصلة، بأحجام عبوات 1 و10.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;ﻗﺪ ﻻ ﺗﺘﻮﻓﺮ ﺑﻌﺾ أﺣﺠﺎم اﻟﻌﺒﻮات ﻓﻲ اﻟﺴﻮق.</p><p dir="RTL"><br /><br />&nbsp;</p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p dir="RTL"><strong>&nbsp;جلاكسو سميث كلاين &ndash; المكتب اﻟﺮﺋﯿﺴﻲ، ﺟﺪة</strong></p><ul><li dir="RTL">الهاتف: +966-12-6536666</li><li dir="RTL">الجوّال:&nbsp; +966-56-904-9882</li><li dir="RTL">البريد اًللكتروني: &nbsp;gcc.medinfo@gsk.com</li><li dir="RTL">الموقع اًلإلكتروني: &nbsp;https://gskpro.com/en-sa/</li><li dir="RTL">ص.ب رقم 55850 ، جدة 21544 ، المملكة العربية السعودية</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية</strong><strong>:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية </strong><strong>(</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاتصال بالرقم الموحد: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">- <strong>جلاكسو </strong><strong>سميث </strong><strong>كلاين</strong><strong> </strong><strong>&ndash; المقر الرئيسي، جدة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهاتف: &nbsp;+966-12-6536666</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجوّال:&nbsp; +966-56-904-9882</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد اًللكتروني: &nbsp;saudi.safety@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع اًلإلكتروني:https://gskpro.com/en-sa/<u> </u>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب. 55850، جدة 21544، المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ھﺬا اﻟﻤﻨﺘﺞ دواء</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدواء مستحضر يؤثر على صحتك، واستهلاكه خلافا للتعليمات يعرضك للخطر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلانى الذى صرفها لك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فالطبيب والصيدلانى هما الخبيران بالدواء، وبنفعه وضرره.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بجميع الأدوية بعيداً عن متناول لأطفال.</p><p dir="RTL">مجلس وزراء الصحة العرب</p><p dir="RTL">اتحاد الصيادلة العرب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﺗﻌﻠﯾﻣﺎت اﻻﺳﺗﺧدام </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">اﻟﻤﻌﻠﻮﻣﺎت اﻟﺘﺎﻟﯿﺔ ﺧﺎﺻﺔ ﺑﺎﺧﺘﺼﺎﺻﯿﻲ اﻟﻄﺐ أو اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ ﻓﻘﻂ:</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻋﻨﺪ ﺗﺨﺰﯾﻦ اﻟﻤُﻌﻠّﻖ، ﻗﺪ ﺗﺘﻜﻮن ﺗﺮﺳﺒﺎت دﻗﯿﻘﺔ ﺑﻠﻮن أﺑﯿﺾ ﻣﺎﺋﻞ ﻟﻼﺻﻔﺮار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾﺠﺐ رج اﻟﻠﻘﺎح ﺟﯿﺪًا ﻗﺒﻞ اﺳﺘﺨﺪاﻣﮫ ﺣﺘﻰ ﯾﺘﺤﻮل ﻟﻤﻌﻠّﻖ ﻣﺘﺠﺎﻧﺲ.</p><p dir="RTL">ﯾﻨﺒﻐﻲ ﻓﺤﺺ اﻟﻠﻘﺎح ﺑﺒﺼﺮك ﻟﻠﺘﺄﻛﺪ ﻣﻦ ﻋﺪم وﺟﻮد أي ﺟﺴﯿﻤﺎت وﻣﻦ ﻋﺪم ﺗﻐﯿﺮ اﻟﻠﻮن ﻗﺒﻞ اﻻﺳﺘﺨﺪام. ﻓﻲ ﺣﺎﻟﺔ وﺟﻮد أي ﺟﺴﯿﻤﺎت ﻏﺮﯾﺒﺔ و/أو ﻣﻼﺣﻈﺔ ﺗﻐﯿﺮ ﻓﻲ اﻟﺠﺎﻧﺐ اﻟﻤﺎدي، ﻻ ﺗﻘﻢ ﺑﺈﻋﻄﺎء اﻟﻠﻘﺎح. إذا ﺗﻮﻓﺮت إﺑﺮﺗﺎن ﺑﻄﻮﻟﯿﻦ ﻣﺨﺘﻠﻔﯿﻦ ﻓﻲ اﻟﻌﺒﻮة، ﻓﺎﺧﺘﺮ اﻹﺑﺮة اﻟﻤﻨﺎﺳﺒﺔ ﻟﻀﻤﺎن اﻻﺳﺘﺨﺪام اﻟﻌﻀﻠﻲ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><img src="data:image/png;base64,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" alt="" width="500" height="326" vspace="0" hspace="0" border="0" style="width:500px;height:326px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p dir="RTL"><strong><u>التخلص من الحقنة</u></strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">ﯾﻨﺒﻐﻲ اﻟﺘﺨﻠّﺺ ﻣﻦ أي ﻣﻨﺘﺞ ﻏﯿﺮ ﻣﺴﺘﻌﻤﻞ أو ﻣﺨﻠﻔﺎت دواﺋﯿﺔ وﻓﻖ اﻟﻤﺘﻄﻠﺒﺎت اﻟﻤﺤﻠﯿﺔ.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﻣﺎﻟﻚ اﻟﺘﺴﻮﯾﻖ اﻟﻤﻌﺘﻤﺪ:</strong></p><p dir="RTL">.Glaxo Saudi Arabia Ltd* ﺟﺪة، اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ</p><p dir="RTL">اﻟﻌﻨﻮان: ص. ب. 22617 ﺟﺪة 21416 &ndash; اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﯿﺔ اﻟﺴﻌﻮدﯾﺔ.</p><p dir="RTL">إحدى شركات GlaxoSmithKline.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اﻟﺸﺮﻛﺔ اﻟﻤُﺼﻨﻌﺔ:&nbsp;</p><p dir="RTL">GSK Vaccines S.r.l.</p><p dir="RTL">Bellaria-Rosia, Sovicille, Siena 53018</p><p dir="RTL">Italy</p><p dir="RTL">اﻟﮭﺎﺗﻒ: (39) 0577243111&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: (39) 0577243401</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رﻗم اﻹﺻدار: GDSv17

ﺗﺎرﯾﺦ اﻹﺻدار: 11 يوليو 2023



Bexsero علامة تجارية مملوكة أو مرخصة لمجموعة شركات .GSK

ﺣﻘوق اﻟطﺑﻊ © ﻟﻌﺎم 2023 ﻣﺣﻔوظﺔ ﻟ GlaxoSmithKline. ﺟﻣﯾﻊ اﻟﺣﻘوق ﻣﺣﻔوظﺔ.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bexsero suspension for injection in pre-filled syringe.
Multicomponent Meningococcal group B Vaccine (recombinant, adsorbed)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 dose (0.5 ml) contains:
Recombinant Neisseria meningitidis group B NHBA fusion protein 1, 2, 3     50 micrograms
Recombinant Neisseria meningitidis group B NadA protein 1, 2, 3	50 micrograms
Recombinant Neisseria meningitidis group B fHbp fusion protein 1,  2, 3	50 micrograms Outer membrane vesicles (OMV) from Neisseria meningitidis group B
strain NZ98/254 measured as amount of total protein containing the
PorA P1.4 2	25 micrograms

1produced in E. coli cells by recombinant DNA technology
2Adsorbed on aluminium hydroxide (0.5 mg Al3+)
3NHBA (Neisserial Heparin Binding Antigen), NadA (Neisseria adhesin A), fHbp (factor H binding protein)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Suspension for injection in pre-filled syringe.
The vaccine is a white opalescent liquid suspension.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by <em>Neisseria meningitidis </em>group B (see &ldquo;Pharmacodynamic effects&rdquo; for information on protection against specific group B strains).</p><p>&nbsp;</p><p>The use of Bexsero should be in accordance with official recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Posology</u></strong></p><p><u>&nbsp;</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:620px"><tbody><tr><td style="vertical-align:top"><p>Age at first dose</p></td><td style="vertical-align:top"><p>Primary Immunisation</p></td><td style="vertical-align:top"><p>Intervals between Primary Doses</p></td><td style="vertical-align:top"><p>Booster</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Infants, 2 months to 5 months a</p></td><td style="vertical-align:top"><p>Three doses each of</p><p>0.5 mL</p></td><td style="vertical-align:top"><p>Not less than 1 month</p></td><td rowspan="2" style="vertical-align:top"><p>Yes, one dose in the second year of life with an interval of at least 6 months between the primary series and booster dose b</p></td></tr><tr><td style="vertical-align:top"><p>Two doses each of</p><p>0.5 mL</p></td><td style="vertical-align:top"><p>Not less than 2 months</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Infants, 6 months</p><p>to 11 months</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Two doses each of</p><p>0.5 mL</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Not less than 2 months</p></td><td style="vertical-align:top"><p>Yes, one dose in the second year of life with an interval of at least 2 months between the primary series and booster dose b</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Children, 12</p><p>months to 23 months</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Two doses each of</p><p>0.5 mL</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>Not less than 2 months</p></td><td style="vertical-align:top"><p>Yes, one dose with an interval of&nbsp;12&nbsp;months to&nbsp;23&nbsp;months between the primary series and booster dose b</p></td></tr><tr><td><p>&nbsp;</p><p>Children, 2 years to 10 years</p></td><td rowspan="2"><p>Two doses each of</p><p>0.5 mL</p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>Not less than 1 month</p></td><td rowspan="2" style="vertical-align:top"><p>A booster dose should be considered in individuals at continued risk of exposure to meningococcal disease, based on official recommendations&nbsp;b</p></td></tr><tr><td><p>&nbsp;</p><p>Adolescents (from 11 years) and adults*</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>a&nbsp;&nbsp; The safety and efficacy of Bexsero in infants less than 8 weeks of age has not yet been established. No data are available.</p><p>b&nbsp;&nbsp; See &ldquo;Pharmacodynamic effects&rdquo;.</p><p>*<sup>&nbsp;&nbsp;&nbsp; </sup>The safety and efficacy of Bexsero in individuals above 50 years of age have not been established.</p><p>Sufficient data are not available on the safety and effectiveness of using Bexsero and other meningococcal group B vaccines interchangeably to complete the vaccination series. Therefore, it is recommended that subjects who receive a first dose of Bexsero complete the vaccination course with Bexsero.</p><p>&nbsp;</p><p><strong><u>Method of Administration</u></strong></p><p>The vaccine is given by deep intramuscular injection, preferably in the anterolateral aspect of the thigh in infants or in the deltoid muscle region of the upper arm in older subjects.</p><p>Separate injection sites must be used if more than one vaccine is administered at the same time.</p><p>For instruction on handling Bexsero before administration, see &ldquo;Use and Handling&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in sections “Formulation and Strength” and “Excipients”.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other vaccines, administration of Bexsero should be postponed in subjects suffering from an acute severe febrile illness. However, the presence of a minor infection, such as cold, should not result in the deferral of vaccination.</p><p>The vaccine must not be injected intravascularly, subcutaneously or intradermally.</p><p>As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.</p><p>Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection (see &ldquo;Adverse Reactions&rdquo;). It is important that procedures are in place to avoid injury from fainting.</p><p>As with any vaccine, vaccination with Bexsero may not protect all vaccine recipients. Bexsero is not expected to provide protection against all circulating meningococcal group B strains (see &ldquo;Pharmacodynamic effects&rdquo;).</p><p>As with many vaccines, healthcare professionals should be aware that a temperature elevation may occur following vaccination of infants and children (less than 2 years of age). Prophylactic administration of antipyretics at the time of and closely after vaccination can reduce the incidence and intensity of post-vaccination febrile reactions. Antipyretic medication should be initiated according to local guidelines in infants and children (less than 2 years of age).</p><p>Individuals with impaired immune responsiveness, whether due to the use of immuno- suppressive therapy, a genetic disorder, or other causes, may have reduced antibody response to active immunisation.</p><p>Immunogenicity data are available in individuals with complement deficiencies, asplenia, or splenic dysfunction (see &ldquo;Immunogenicity&rdquo;).</p><p>Individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) remain at increased risk of invasive disease caused by Neisseria meningitidis group B even following vaccination with Bexsero.</p><p>The safety and efficacy of Bexsero in individuals above 50 years of age have not been established.</p><p>There are limited data in patients with chronic medical conditions.</p><p>&nbsp;</p><p>The potential risk of apnoea and the need for respiratory monitoring for 48-72h should be considered when administering the primary immunisation series to very premature infants (born &le; 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.</p><p>&nbsp;</p><p>Kanamycin is used in early manufacturing process and is removed during the later stages of manufacture. If present, kanamycin levels in the final vaccine are less than 0.01 micrograms per dose. The safe use of Bexsero in kanamycin-sensitive individuals has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use with other vaccines</u></p><p>Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines: diphtheria, tetanus, acellular pertussis, <em>Haemophilus influenzae </em>type b, inactivated poliomyelitis, hepatitis B, heptavalent pneumococcal conjugate, measles, mumps, rubella, varicella, and meningococcal groups A, C, W, Y conjugate.</p><p>&nbsp;</p><p>Clinical studies demonstrated that the immune responses of the co-administered routine vaccines were unaffected by concomitant administration of Bexsero. Inconsistent results were seen across studies for responses to inactivated poliovirus type 2 and pneumococcal conjugate serotype 6B but these data do not suggest clinically significant interference.</p><p>&nbsp;</p><p>The safety profiles of the co-administered vaccines were unaffected by concomitant administration of Bexsero with the exception of more frequent occurrence of fever, tenderness at the injection site, change in eating habits and irritability. Prophylactic use of paracetamol reduces the incidence and severity of fever without affecting the immunogenicity of either Bexsero or routine vaccines. The effect of antipyretics other than paracetamol on the immune response has not been studied.</p><p>&nbsp;</p><p>Concomitant administration of Bexsero with vaccines other than those mentioned above has not been studied.</p><p>Administration of vaccines containing whole cell pertussis concomitantly with Bexsero has not been studied and thus is not recommended.</p><p>&nbsp;</p><p>When given concomitantly with other vaccines Bexsero must be administered at separate injection sites (see &ldquo;Method of Administration&rdquo;).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on fertility in humans.</p><p>There were no effects on female fertility in animal studies.</p><p>There were no effects on the mating performance or fertility of female rabbits in an embryofoetal and developmental toxicity study in which rabbits were intramuscularly injected with Bexsero 35, 21, and 7 days prior to mating and on gestation days 7 and 20. Male fertility has not been assessed in animals<em>.</em></p><p><em>&nbsp;</em></p><p><strong>Pregnancy</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_6c09bfe4-8af9-4580-a2ab-58808d9a8656
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>Insufficient clinical data on exposed pregnancies are available.</p><p>&nbsp;</p><p>The potential risk for pregnant women is unknown. Nevertheless, vaccination should not be withheld when there is a clear risk of exposure to meningococcal infection.</p><p>&nbsp;</p><p>There was no evidence of maternal or foetal toxicity, and no effects on pregnancy, maternal behaviour, female fertility, or postnatal development in a study in which female rabbits received Bexsero at approximately 10 times the human dose equivalent based on body weights.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Lactation</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5f7d5703-537c-43ac-ad36-626c248fdd0e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&nbsp;</p><p>Information on the safety of the vaccine to women and their children during breast- feeding is not available. The benefit-risk ratio must be examined before making the decision to immunise during breast-feeding.</p><p>&nbsp;</p><p>No adverse reactions were seen in vaccinated maternal rabbits or in their offspring through day 29 of lactation. Bexsero was immunogenic in maternal animals vaccinated prior to lactation, and antibodies were detected in the offspring, but antibody levels in milk were not determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bexsero has no or negligible influence on the ability to drive and use machines. However, some of the effects mentioned under &ldquo;Adverse Reactions&rdquo; may temporarily affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical trial data</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_950582fc-0f21-4278-b423-1c8ffc42120a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The safety of Bexsero was evaluated in 13 studies including 9 randomised controlled clinical trials with 7802 subjects (from 2 months of age) who received at least one dose of Bexsero and in a subsequent study in 974 young adults. Among Bexsero recipients, 5849 were infants and children (less than 2 years of age), 250 were children (2 to 10 years of age) and 2677 were adolescents and adults. Of the subjects who received primary infant series of Bexsero, 3285 received a booster dose in the second year of life. Data for 988 infants and children (less than 2 years of age) and 801 children (2 to 10 years of age) exposed to Bexsero in subsequent studies have additionally been evaluated. The safety of Bexsero was also evaluated in a randomised, controlled, observer-blind trial with 1803 subjects (10&nbsp;to&nbsp;25 years of age) who received at least one dose of Bexsero.</p><p>&nbsp;</p><p>In infants and children (less than 2 years of age) the most common local and systemic adverse reactions observed in clinical trials were tenderness and erythema at the injection site, fever and irritability.</p><p>&nbsp;</p><p>In clinical studies in infants vaccinated at 2, 4 and 6 months of age, fever (&ge; 38&deg;C) was reported by 69% to 79% of subjects when Bexsero was co-administered with routine vaccines (containing the following antigens: pneumococcal 7-valent conjugate, diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis and <em>Haemophilus influenzae </em>type b) compared with 44% to 59% of subjects receiving the routine vaccines alone. Higher rates of antipyretic use were also reported for infants vaccinated with Bexsero and routine vaccines. When Bexsero was given alone, the frequency of fever was similar to that associated with routine infant vaccines administered during clinical trials. When fever occurred, it generally followed a predictable pattern, with the majority resolving by the day after vaccination.<strong> </strong></p><p>&nbsp;</p><p>In adolescents and adults the most common local and systemic adverse reactions observed were pain at the injection site, malaise and headache.<strong> </strong></p><p>&nbsp;</p><p>No increase in the incidence or severity of the adverse reactions was seen with subsequent doses of the vaccination series.</p><p>&nbsp;</p><p>Adverse reactions (following primary immunisation or booster dose) considered as being at least possibly related to vaccination have been categorised by frequency.</p><p>Frequencies are defined as follows: Very common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/10</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/100 to &lt;1/10</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/1000 to &lt;1/100 Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/10000 to &lt;1/1000</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1/10000</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong><em>Infants and children (up to 10 years of age)</em></strong><!--[if supportFields]><b><i><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_fb51427c-cb75-4e89-a4ed-c44c1c6d8676 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></i></b><![endif]--></p><p><u>Metabolism and nutrition disorders </u>Very common: eating disorders</p><p>&nbsp;</p><p><u>Nervous system disorders</u></p><p>Very common: sleepiness, unusual crying, headache Uncommon: seizures (including febrile seizures)</p><p>&nbsp;</p><p><u>Vascular disorders</u></p><p>Uncommon: pallor (rare after booster) Rare: Kawasaki syndrome</p><p>&nbsp;</p><p><u>Gastrointestinal disorders</u></p><p>Very common: diarrhoea, vomiting (uncommon after booster)</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>Very common: rash (children aged 12 to 23 months) (uncommon after booster) Common: rash (infants and children 2 to 10 years of age)</p><p>Uncommon: eczema</p><p>Rare: urticaria</p><p>&nbsp;</p><p><u>Musculoskeletal and connective tissue disorders </u>Very common: arthralgia</p><p><u>&nbsp;</u></p><p><u>General disorders and administration site conditions</u></p><p>Very common: fever (&ge;38&deg;C), injection site tenderness (including severe injection site tenderness defined as crying when injected limb is moved), injection site erythema, injection site swelling, injection site induration, irritability</p><p>Uncommon: fever (&ge;40&deg;C)</p><p><strong><em>Adolescents (from 11 years of age) and adults</em></strong><!--[if supportFields]><b><i><span lang=EN-GB
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_7a5fa097-b047-4390-81f9-6d6387b591b4 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></i></b><![endif]--></p><p><u>Nervous system disorders </u>Very common: headache</p><p>&nbsp;</p><p><u>Gastrointestinal disorders </u>Very common: nausea</p><p>&nbsp;</p><p><u>Musculoskeletal and connective tissue disorders </u>Very common: myalgia, arthralgia</p><p>&nbsp;</p><p><u>General disorders and administration site conditions</u></p><p>Very common: injection site pain (including severe injection site pain defined as unable to perform normal daily activity), injection site swelling, injection site induration, injection site erythema, malaise</p><p>&nbsp;</p><p><strong>Post-marketing data</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_cce2a97b-fcbb-43fe-b997-94cf4dc33539 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>In addition to reports in clinical trials, worldwide voluntary reports of adverse reactions received for Bexsero since market introduction are listed below. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.</p><p><u>Blood and lymphatic system disorders</u></p><p>Lymphadenopathy</p><p><u>Immune system disorders</u></p><p>Allergic reactions (including anaphylactic reactions).</p><p><u>Nervous system disorders</u></p><p>Hypotonic-hyporesponsive episode, syncope or vasovagal responses to injection</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>Rash (adolescents from 11 years of age and adults)</p><p><u>General disorders and administration site conditions</u></p><p>Fever (adolescents from 11 years of age and adults), injection site reactions (including extensive swelling of the vaccinated limb, blisters at or around the injection site and injection site nodule which may persist for more than one month)</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Reporting hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul><p><strong>&nbsp;-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>s</u>audi.safety@gsk.com<u>&nbsp; </u></li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience of overdose is limited. In the event of overdose, monitoring of vital functions and possible symptomatic treatment is recommended.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATC code</strong></p><p><strong>&nbsp;</strong></p><p>Pharmacotherapeutic group: meningococcal vaccines, ATC code: J07AH09</p><p><strong>&nbsp;</strong></p><p><strong>Mechanism of action</strong></p><p><strong>&nbsp;</strong></p><p>Immunisation with Bexsero is intended to stimulate the production of bactericidal antibodies that recognise the vaccine antigens NHBA, NadA, fHbp, and PorA P1.4 (the immunodominant antigen present in the OMV component) and are expected to be protective against Invasive Meningococcal Disease (IMD). As these antigens are variably expressed by different strains, meningococci that express them at sufficient levels are susceptible to killing by vaccine-elicited antibodies. Bactericidal antibodies are measured by the serum bactericidal assay using human serum as the source of complement (hSBA). The Meningococcal Antigen Typing System (MATS) was developed to relate antigen profiles of different strains of meningococcal group B bacteria to killing of the strains in the hSBA, and ultimately to predict breadth of strain coverage.</p><p>&nbsp;</p><p>The vaccine antigens present in Bexsero are also expressed by strains belonging to meningococcal groups other than group B. Limited data suggest protection against some non-group B strains, however, the extent is not yet determined (see &ldquo;Data generated in real-world settings&rdquo;).</p><p><strong>Pharmacodynamic effects</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Clinical efficacy</u></strong><!--[if supportFields]><b><u
style='text-underline:thick'><span lang=EN-GB style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_b0aa6a8c-d9b3-4f7d-bd92-de8c8225210f
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></u></b><![endif]--><strong><u>&nbsp;</u></strong><!--[if supportFields]><b><u
style='text-underline:thick'><span lang=EN-GB style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></u></b><![endif]--></p><p><strong>&nbsp;</strong></p><p>The efficacy of Bexsero has not been directly evaluated through clinical trials. Vaccine efficacy has been inferred by demonstrating the induction of serum bactericidal antibody responses to each of the vaccine antigens (see &ldquo;Immunogenicity&rdquo;). Immunological vaccine effectiveness has been demonstrated using endogenous complement hSBA (enc-hSBA) against a broad panel of 110 diverse <em>Neisseria meningitidis</em> serogroup B strains (see &ldquo;Immunological vaccine effectiveness&rdquo;). Vaccine effectiveness and impact have been demonstrated in real-world settings (see &ldquo;Data generated in real-world settings&rdquo;).</p><p>&nbsp;</p><p><strong><u>Data generated from clinical trials</u></strong></p><p><u>Immunological vaccine effectiveness</u></p><p>In a clinical trial, the immunological vaccine effectiveness of Bexsero was measured by a bactericidal assay using the intrinsic complement present in the serum of each vaccine recipient (endogenous complement hSBA, enc-hSBA). This assay captures the bactericidal effect of the combined antibody responses elicited by all serogroup B meningococcal vaccine antigens and enables the assessment of the protection versus a broad panel of 110 diverse <em>Neisseria</em><em> meningitidis</em> serogroup B disease-causing strains. This panel represents approximately 89% of the MenB isolates circulating worldwide from 2000-2018, ranging from 87% for European isolates to &ge;90% of the isolates in Canada, U.S. and Australia. In addition, the panel included strains with a genetic profile comparable to that of the hypervirulent clusters frequently associated with outbreaks and epidemic disease.</p><p>The immunological effectiveness of Bexsero was evaluated in a phase 3, randomised, controlled, observer-blind, trial in individuals aged 10 through 25 years randomised to receive two doses of Bexsero using a 0,&nbsp;2-month schedule (n=839) or a 0,&nbsp;6-month schedule (n=815), or a single dose of GSK&nbsp;MenACWY vaccine as a control (n=172), one month after the last administered dose.</p><p>Test-based immunological vaccine effectiveness, based on the ratio between the percentages of samples lacking bactericidal activity against the panel of 110 <em>Neisseria</em><em> meningitidis</em> group&nbsp;B invasive disease strains in participants who received two doses of Bexsero 2&nbsp;or 6&nbsp;months apart and in participants receiving a single dose of GSK&nbsp;MenACWY vaccine, is presented in Table 1.</p><p><strong>Table 1. Immunological vaccine effectiveness (test-based) following two doses of Bexsero administered 2 or 6 months apart in participants aged 10 through 25 years</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Group</strong></p></td><td style="vertical-align:bottom"><p><strong>Number of samples</strong></p></td><td style="vertical-align:bottom"><p><strong>Number of samples without bactericidal serum activity</strong></p></td><td style="vertical-align:bottom"><p><strong>% of samples without bactericidal serum activity</strong></p></td><td style="vertical-align:bottom"><p><strong>RR</strong></p><p><strong>(97.5% CI)</strong></p></td><td style="vertical-align:bottom"><p><strong>Immunological vaccine effectiveness<sup>*</sup></strong></p><p><strong>(97.5% CI)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Bexsero</strong></p><p><strong>0</strong><strong>, 2 months</strong></p></td><td style="vertical-align:top"><p>27569</p></td><td style="vertical-align:top"><p>4648</p></td><td style="vertical-align:top"><p>17</p></td><td rowspan="2" style="vertical-align:top"><p>0.21</p><p>(0.20-0.23)</p></td><td rowspan="2" style="vertical-align:top"><p>79</p><p>(77<sup>**</sup>-80)</p></td></tr><tr><td style="vertical-align:top"><p><strong>GSK MenACWY</strong></p></td><td style="vertical-align:top"><p>4374</p></td><td style="vertical-align:top"><p>3456</p></td><td style="vertical-align:top"><p>79</p></td></tr><tr><td style="vertical-align:top"><p><strong>Bexsero</strong></p><p><strong>0, 6 months</strong></p></td><td style="vertical-align:top"><p>26142</p></td><td style="vertical-align:top"><p>3777</p></td><td style="vertical-align:top"><p>14</p></td><td rowspan="2" style="vertical-align:top"><p>0.18</p><p>(0.17-0.20)</p></td><td rowspan="2" style="vertical-align:top"><p>82</p><p>(80<sup>**</sup>-83)</p></td></tr><tr><td style="vertical-align:top"><p><strong>GSK MenACWY</strong></p></td><td style="vertical-align:top"><p>4374</p></td><td style="vertical-align:top"><p>3456</p></td><td style="vertical-align:top"><p>79</p></td></tr></tbody></table><p>Study V72_72.</p><p>Abbreviations: CI&nbsp;=&nbsp;Confidence interval; RR&nbsp;=&nbsp;Relative Risk.</p><p><sup>*</sup><sup> </sup>Immunological vaccine effectiveness is defined as 1- RR&nbsp;=&nbsp;(1- percentage of samples without bactericidal serum activity measured by enc-hSBA in the Bexsero group / percentage of samples without bactericidal serum activity in the GSK&nbsp;MenACWY group) x 100%.</p><p><sup>** </sup>Pre-specified criterion met.</p><p>Responder-based immunological vaccine effectiveness assesses the percentages of participants whose serum kills &ge;70% of the tested strains. At one month after the second dose, the responder-based immunological effectiveness in participants receiving two doses of Bexsero 2 months apart was 85% (97.5%&nbsp;CI:&nbsp;82%-88%) and 90% (97.5%&nbsp;CI:&nbsp;87%-92%) in those receiving doses 6 months apart.</p><p>The predefined success criterion (lower limit of the 2-sided 97.5% CI for immunological vaccine effectiveness &gt;65%) was met for both endpoints with both dosing schedules.</p><p>&nbsp;</p><p><strong><u>Data generated in real-world settings</u></strong></p><p><u>Vaccine effectiveness </u></p><p>A matched case-control study on IMD prevention was conducted with Bexsero in Portugal between October 2014 and March 2019 in infants, children, and adolescents up to 18 years of age. The study showed a 79% statistically significant vaccine effectiveness [Odds Ratio 0.21 (95%&nbsp;CI:&nbsp;0.08‑0.55)] against IMD caused by <em>Neisseria meningitidis</em> group B (MenB IMD) in individuals fully vaccinated for age based on the recommendations of the Portuguese Society of Paediatrics.</p><p><u>Impact of vaccination on disease incidence</u></p><p>In the UK, Bexsero was introduced into the national immunisation programme (NIP) in September 2015 using a two-dose schedule in infants (at 2 and 4 months of age) followed by a booster dose (at 12 months of age). In this context, Public Health England (PHE) conducted a 3‑year observational study at the national level covering the entire birth cohort.</p><p>After three years of the programme, a statistically significant reduction of 75% [Incidence Rate Ratio (IRR) 0.25 (95%&nbsp;CI:&nbsp;0.19‑0.36)] in MenB IMD cases was observed in vaccine-eligible infants, irrespective of the infants&rsquo; vaccination status or predicted meningococcal group B strain coverage.</p><p>PHE also estimated the direct impact of Bexsero on <em>Neisseria meningitidis</em> group W IMD (MenW IMD) in birth cohorts fully eligible for Bexsero. In the four years from September 2015 to August 2019, a statistically significant reduction of 69% [IRR 0.31 (95%&nbsp;CI&nbsp;0.20‑0.67)] in MenW IMD cases was observed on top of the indirect (herd) protection provided through an existing meningococcal ACWY vaccination programme in adolescents.</p><p>In South Australia, vaccination impact data were generated from a large-scale trial conducted between January 2017 and June 2019 in high school students 16 through 19 years of age. Participants received two doses of Bexsero with a one‑ to three‑month interval. A statistically significant reduction of 71% (95%&nbsp;CI:&nbsp;15‑90) in MenB IMD cases was observed in the two years from July 2017 to June 2019.</p><p><strong><u>Immunogenicity</u></strong><!--[if supportFields]><b><u
style='text-underline:thick'><span lang=EN-GB style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_a251bb0d-08e1-4412-a9aa-d56fee7f84b9
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></u></b><![endif]--><strong><u>&nbsp;</u></strong><!--[if supportFields]><b><u
style='text-underline:thick'><span lang=EN-GB style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></u></b><![endif]--></p><p>Serum bactericidal antibody responses to each of the vaccine antigens NadA, fHbp, NHBA and PorA P1.4 were evaluated using a set of four meningococcal group B reference strains. The immune response of Bexsero was assessed by measuring the production of bactericidal antibodies against each of the vaccine antigens, using the serum bactericidal activity (SBA) assay with human serum as the source of exogenous complement (hSBA). Data are not available from all vaccine schedules using the reference strain for NHBA.</p><p>Most of the primary immunogenicity studies were conducted as randomised, controlled, multicentre, clinical trials. Immunogenicity was evaluated in infants, children, adolescents and adults.</p><p>&nbsp;</p><p><u>Immunogenicity in infants and children</u></p><p>In infant studies, participants received three doses of Bexsero either at 2, 4 and 6 or 2, 3 and 4 months of age and a booster dose in their second year of life, as early as 12 months of age. Sera were obtained both before vaccination, one month after the third vaccination (Table 2) and one month after booster vaccination (Table 3). In an extension study the persistence of the immune response was assessed one year after the booster dose (Table 3). The immunogenicity after two or three doses followed by a booster has been evaluated in infants 2 months to 5 months of age in another clinical study. The immunogenicity after two doses has been also documented in another study in infants 6 months to 8 months of age at enrolment (Table 4).</p><p>&nbsp;</p><p>Previously unvaccinated children also received two doses in the second year of life, with antibody persistence being measured at one year after the second dose (Table 4).</p><p>&nbsp;</p><p><em><u>Immunogenicity in infants 2 months to 5 months of age Three-dose primary series followed by a booster</u></em></p><p>Immunogenicity results at one month after three doses of Bexsero administered at 2, 3, 4</p><p>and 2, 4, 6 months of age are summarised in Table 2. Bactericidal antibody responses one month after the third vaccination against meningococcal reference strains were high against the fHbp, NadA and PorA P1.4 antigens at both Bexsero vaccination schedules.&nbsp; The bactericidal responses against the NHBA antigen were also high in infants vaccinated at the 2, 4, 6-month schedule, but this antigen appeared to be less immunogenic at the 2, 3, 4-month schedule. The clinical consequences of the reduced immunogenicity of the NHBA antigen at this schedule are not known.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 2. Serum bactericidal antibody responses at 1 month following the third dose of Bexsero given at 2, 3, 4 or 2, 4, 6 months of age</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a8c9b6f3-7131-4363-99be-1c26c7237da6 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Antigen</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Study V72P13 2, 4, 6 months</strong></p></td><td style="vertical-align:top"><p><strong>Study V72P12 2, 3, 4 months</strong></p></td><td style="vertical-align:top"><p><strong>Study V72P16 2, 3, 4 months</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>fHbp</strong></p></td><td style="vertical-align:top"><p>% seropositive* (95% CI)</p></td><td style="vertical-align:top"><p>N=1149 100% (99-100)</p></td><td style="vertical-align:top"><p>N=273 99% (97-100)</p></td><td style="vertical-align:top"><p>N=170 100% (98-100)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT** (95% CI)</p></td><td style="vertical-align:top"><p>91</p><p>(87-95)</p></td><td style="vertical-align:top"><p>82</p><p>(75-91)</p></td><td style="vertical-align:top"><p>101</p><p>(90-113)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>NadA</strong></p></td><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>N=1152 100% (99-100)</p></td><td style="vertical-align:top"><p>N=275 100% (99-100)</p></td><td style="vertical-align:top"><p>N=165 99% (97-100)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>635</p><p>(606-665)</p></td><td style="vertical-align:top"><p>325</p><p>(292-362)</p></td><td style="vertical-align:top"><p>396</p><p>(348-450)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>PorA P1.4</strong></p></td><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>N=1152 84% (82-86)</p></td><td style="vertical-align:top"><p>N=274 81% (76-86)</p></td><td style="vertical-align:top"><p>N=171 78% (71-84)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>14</p><p>(13-15)</p></td><td style="vertical-align:top"><p>11</p><p>(9.14-12)</p></td><td style="vertical-align:top"><p>10</p><p>(8.59-12)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>NHBA</strong></p></td><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>N=100 84% (75-91)</p></td><td style="vertical-align:top"><p>N=112 37% (28-46)</p></td><td style="vertical-align:top"><p>N=35 43% (26-61)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>16</p><p>(13-21)</p></td><td style="vertical-align:top"><p>3.24</p><p>(2.49-4.21)</p></td><td style="vertical-align:top"><p>3.29</p><p>(1.85-5.83)</p></td></tr></tbody></table><p>* % seropositive = the percentage of subjects who achieved an hSBA &ge; 1:5.</p><p>** GMT = geometric mean titre.</p><p>&nbsp;</p><p>Data on bactericidal antibody persistence at 8 months after Bexsero vaccination at 2, 3&nbsp;&nbsp; and 4 months of age, and at 6 months after Bexsero vaccination at 2, 4 and 6 months of age (pre-booster time point) and booster data after a fourth dose of Bexsero administered at 12 months of age are summarised in Table 3. Persistence of the immune response one year after the booster dose is also presented in Table 3.</p><p>&nbsp;</p><p><strong>Table 3. Serum bactericidal antibody responses following a booster at 12 months of age after a primary series administered at 2, 3 and 4 or 2, 4 and 6 months of age, and persistence of bactericidal antibody one year after the booster</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_5c5ac35b-192b-4f98-99ce-82344aff492b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:100%"><tbody><tr><td><p><strong>Antigen</strong></p></td><td><p>&nbsp;</p></td><td><p><strong>2, 3, 4, 12 months</strong></p></td><td><p><strong>2, 4, 6, 12 months</strong></p></td></tr><tr><td rowspan="3"><p><strong>fHbp</strong></p></td><td><p>pre-booster*</p><p>% seropositive** (95% CI)</p><p>hSBA GMT*** (95% CI)</p></td><td><p>N=81</p><p>58% (47-69)</p><p>5.79 (4.54-7.39)</p></td><td><p>N=426</p><p>82% (78-85)</p><p>10 (9.55-12)</p></td></tr><tr><td><p>1 month after booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td><p>N=83</p><p>100% (96-100)</p><p>135 (108-170)</p></td><td><p>N=422</p><p>100% (99-100)</p><p>128 (118-139)</p></td></tr><tr><td><p>12 months after booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td><p>-</p></td><td><p>N=299</p><p>62% (56-67)</p><p>6.5 (5.63-7.5)</p></td></tr><tr><td rowspan="3"><p><strong>NadA</strong></p></td><td><p>pre-booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td><p>N=79</p><p>97% (91-100)</p><p>63 (49-83)</p></td><td><p>N=423</p><p>99% (97-100)</p><p>81 (74-89)</p></td></tr><tr><td><p>1 month after booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td><p>N=84</p><p>100% (96-100)</p><p>1558 (1262-1923)</p></td><td><p>N=421</p><p>100% (99-100)</p><p>1465 (1350-1590)</p></td></tr><tr><td><p>12 months after booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td><p>-</p></td><td><p>N=298</p><p>97% (95-99)</p><p>81 (71-94)</p></td></tr><tr><td rowspan="3"><p><strong>PorA P1.4</strong></p></td><td><p>pre-booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td><p>N=83</p><p>19% (11-29)</p><p>1.61 (1.32-1.96)</p></td><td><p>N=426</p><p>22% (18-26)</p><p>2.14 (1.94-2.36)</p></td></tr><tr><td><p>1 month after booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td><p>N=86</p><p>97% (90-99)</p><p>47 (36-62)</p></td><td><p>N=424</p><p>95% (93-97)</p><p>35 (31-39)</p></td></tr><tr><td><p>12 months after booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td><p>-</p></td><td><p>N=300</p><p>17% (13-22)</p><p>1.91 (1.7-2.15)</p></td></tr><tr><td rowspan="3"><p><strong>NHBA</strong></p></td><td><p>pre-booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>N=69</p><p>25% (15-36)</p><p>2.36 (1.75-3.18)</p></td><td><p>N=100</p><p>61% (51-71)</p><p>8.4 (6.4-11)</p></td></tr><tr><td><p>1 month after booster % seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>N=67</p><p>76% (64-86)</p><p>12 (8.52-17)</p></td><td><p>N=100</p><p>98% (93-100)</p><p>42 (36-50)</p></td></tr><tr><td style="vertical-align:top"><p>12 months after booster</p><p>% seropositive (95% CI)</p><p>hSBA GMT (95% CI)</p></td><td><p>-</p></td><td><p>N=291<br />36% (31-42)</p><p>3.35 (2.88-3.9)</p></td></tr></tbody></table><p>* pre-booster time point represents persistence of bactericidal antibody at 8 months after Bexsero vaccination at 2, 3 and 4 months of age and 6 months after Bexsero vaccination at 2, 4 and 6 months of age.</p><p>** % seropositive = the percentage of subjects who achieved an hSBA &ge; 1:5.</p><p>*** GMT = geometric mean titre.</p><p><em><u>Two-dose primary series followed by a booster</u></em></p><p>The immunogenicity after two doses (at 3 and a half and 5 months of age) or three doses (at 2 and a half, 3 and a half and 5 months of age) of Bexsero followed by a booster has been evaluated in an additional phase 3 clinical study. The percentages of seropositive subjects (i.e. achieving an hSBA of at least 1:4) ranged from 44% to 100% one month after the second dose and from 55% to 100% one month after the third dose. At one&nbsp;&nbsp; month following a booster administered 6 months after the last dose, the percentages of seropositive subjects ranged from 87% to 100% for the two-dose schedule, and from 83% to 100% for the three-dose schedule.</p><p>&nbsp;</p><p>Antibody persistence was evaluated in an extension study in children 3 to 4 years of age. Comparable percentages of subjects were seropositive at 2 to 3 years after being previously vaccinated with either two doses followed by a booster of Bexsero (ranging from 35% to 91%) or three doses followed by a booster (ranging from 36% to 84%). In&nbsp;&nbsp; the same study the response to an additional dose administered 2 to 3 years after the booster was indicative of immunological memory as shown by a robust antibody response against all Bexsero antigens, ranging from 81% to 100% and from 70% to 99%, respectively.&nbsp; These observations are consistent with adequate priming in infancy with both a two-dose and a three-dose primary series followed by a booster of Bexsero.</p><p>&nbsp;</p><p><em><u>Immunogenicity in infants 6 to 11 months and children 12 to 23 months of age</u></em></p><p>The immunogenicity after two doses administered two months apart in children 6 months to 23 months of age has been documented in two studies whose results are summarised in Table 4. Against each of the vaccine antigens, seroresponse rates and hSBA GMTs were high and similar after the two-dose series in infants 6-8 months of age and children 13-15 months of age. Data on antibody persistence one year after the two doses at 13 and 15 months of age are also summarised in Table 4.<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_9d66d1da-369e-48d8-b441-dde0052572d5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:12.0pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Table 4. Serum bactericidal antibody responses following Bexsero vaccination at 6 and 8 months of age or 13 and 15 months of age and persistence of bactericidal antibody one year after the two doses at 13 and 15 months of age</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ea01d47d-8d57-4efc-a3fb-9978d1ab0f09 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><tbody><tr><td rowspan="4"><p><strong>Antigen</strong></p></td><td rowspan="4"><p>&nbsp;</p></td><td colspan="2"><p><strong>Age range</strong></p></td></tr><tr><td><p><strong>6 to 11 </strong></p><p><strong>months of age</strong></p></td><td><p><strong>12 to 23 </strong></p><p><strong>months of age </strong></p></td></tr><tr><td colspan="2"><p><strong>Age of vaccination</strong></p></td></tr><tr><td><p><strong>6, 8 months</strong></p></td><td><p><strong>13, 15 months</strong></p></td></tr><tr><td rowspan="6"><p><strong>fHbp</strong></p></td><td style="vertical-align:top"><p><u>1 month after 2<sup>nd</sup> dose</u></p></td><td style="vertical-align:top"><p>N=23</p></td><td style="vertical-align:top"><p>N=163</p></td></tr><tr><td style="vertical-align:top"><p>% seropositive* (95% CI)</p></td><td style="vertical-align:top"><p>100% (85-100)</p></td><td style="vertical-align:top"><p>100% (98-100)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT** (95% CI)</p></td><td style="vertical-align:top"><p>250 (173-361)</p></td><td style="vertical-align:top"><p>271 (237-310)</p></td></tr><tr><td style="vertical-align:top"><p><u>12 months after 2<sup>nd</sup> dose</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=68</p></td></tr><tr><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>74% (61-83)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>14 (9.4-20)</p></td></tr><tr><td rowspan="6"><p><strong>NadA</strong></p></td><td style="vertical-align:top"><p><u>1 month after 2<sup>nd</sup> dose</u></p></td><td style="vertical-align:top"><p>N=23</p></td><td style="vertical-align:top"><p>N=164</p></td></tr><tr><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>100% (85-100)</p></td><td style="vertical-align:top"><p>100% (98-100)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>534 (395-721)</p></td><td style="vertical-align:top"><p>599 (520-690)</p></td></tr><tr><td style="vertical-align:top"><p><u>12 months after 2<sup>nd</sup> dose</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=68</p></td></tr><tr><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>97% (90-100)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>70 (47-104)</p></td></tr><tr><td rowspan="6"><p><strong>PorA P1.4</strong></p></td><td style="vertical-align:top"><p><u>1 month after 2<sup>nd</sup> dose</u></p></td><td style="vertical-align:top"><p>N=22</p></td><td style="vertical-align:top"><p>N=164</p></td></tr><tr><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>95% (77-100)</p></td><td style="vertical-align:top"><p>100% (98-100)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>27 (21-36)</p></td><td style="vertical-align:top"><p>43 (38-49)</p></td></tr><tr><td style="vertical-align:top"><p><u>12 months after 2<sup>nd</sup> dose</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=68</p></td></tr><tr><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>18% (9-29)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.65 (1.2-2.28)</p></td></tr><tr><td rowspan="6"><p><strong>NHBA</strong></p></td><td style="vertical-align:top"><p><u>1 month after 2<sup>nd</sup> dose</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=46</p></td></tr><tr><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>63% (48-77)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>11 (7.07-16)</p></td></tr><tr><td style="vertical-align:top"><p><u>12 months after 2<sup>nd</sup> dose</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=65</p></td></tr><tr><td style="vertical-align:top"><p>% seropositive (95% CI)</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>38% (27-51)</p></td></tr><tr><td style="vertical-align:top"><p>hSBA GMT (95% CI)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3.7 (2.15-6.35)</p></td></tr></tbody></table><p>* % seropositive = the percentage of subjects who achieved an hSBA &ge; 1:4 (in the 6 to 11 months range of age) and an hSBA &ge; 1:5 (in the 12 to 23 months range of age).</p><p>** GMT = geometric mean titre.</p><p>The seroresponse rates were 98% to 100% against all strains following a booster dose given at approximately one year after the administration of two doses at 13 and 15 months of age.</p><p>&nbsp;</p><p><em><u>Immunogenicity in children 2 to 10 years of age</u></em></p><p>The immunogenicity after two doses of Bexsero administered either one or two months apart in children 2 to 10 years of age has been evaluated in an initial phase 3 clinical study and its extension. In the initial study, whose results are summarised in Table 5, participants received two doses of Bexsero two months apart. The seroresponse rates and hSBA GMTs were high after the two-dose schedule in children against each of the vaccine antigens (Table 5).</p><p>&nbsp;</p><p><strong>Table 5. Serum bactericidal antibody responses at 1 month following the second dose of Bexsero given to children 2-10 years of age following a 0, 2-month schedule</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:11.5pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_57b75695-4cfa-432e-ad50-8454dfc92d13 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:11.5pt;line-height:100%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:101%"><tbody><tr><td><p><strong>Antigen</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>2 to 5 years of age</strong></p></td><td><p><strong>6 to 10 years of age</strong></p></td></tr><tr><td rowspan="2"><p><strong>fHbp</strong></p></td><td><p>% seropositive*</p><p>(95% CI)</p></td><td><p>N=99</p><p>100% (96-100)</p></td><td><p>N=287</p><p>99% (96-100)</p></td></tr><tr><td><p>hSBA GMT**</p><p>(95% CI)</p></td><td><p>140</p><p>(112-175)</p></td><td><p>112</p><p>(96-130)</p></td></tr><tr><td rowspan="2"><p><strong>NadA</strong></p></td><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>N=99</p><p>99% (95-100)</p></td><td><p>N=291</p><p>100% (98-100)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>584</p><p>(466-733)</p></td><td><p>457</p><p>(392-531)</p></td></tr><tr><td rowspan="2"><p><strong>PorA P1.4</strong></p></td><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>N=100</p><p>98% (93-100)</p></td><td><p>N=289</p><p>99% (98-100)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>42</p><p>(33-55)</p></td><td><p>40</p><p>(34-48)</p></td></tr><tr><td rowspan="2"><p><strong>NHBA</strong></p></td><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>N=95</p><p>91% (83-96)</p></td><td><p>N=275</p><p>95% (92-97)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>23</p><p>(18-30)</p></td><td><p>35</p><p>(29-41)</p></td></tr></tbody></table><p>* % seropositive = the percentage of subjects who achieved an hSBA &ge; 1:4 (against reference strains for fHbp, NadA, PorA P1.4 antigens) and an hSBA &ge; 1:5 (against reference strain for NHBA antigen).</p><p>** GMT = geometric mean titre.</p><p>&nbsp;</p><p>In the extension study, in which two doses of Bexsero were administered one month apart in unvaccinated children, high percentages of subjects were seropositive one month after the second dose. An early immune response after the first dose was also evaluated. The percentages of seropositive subjects (i.e. achieving an hSBA of at least 1:4) across strains ranged from 46% to 95% at one month after the first dose and from 69% to 100% at one month after the second dose.</p><p>&nbsp;</p><p>This study also evaluated antibody persistence and the response to a booster dose in children who received the two-dose primary series at 2-5 or 6-10 years of age. After 24-36 months, the percentages of seropositive subjects (i.e. achieving an hSBA of at least 1:4) declined, ranging across strains from 21% to 74% in children 4-7 years of age and from 47% to 86% in children 8-12 years of age. The response to a booster dose administered 24-36 months after the primary series was indicative of immunological memory as the percentages of seropositive subjects ranged across strains from 93% to 100% in children 4-7 years of age and from 96% to 100% in children 8-12 years of age.</p><p>&nbsp;</p><p><em><u>Immunogenicity in adolescents (from 11 years of age) and adults</u></em></p><p>Adolescents received two doses of Bexsero with one, two or six-month intervals between doses; these data are summarised in Tables 6 and 7. As early as one month post- vaccination with the first dose, percentages of subjects who achieved an hSBA &ge; 1:4 ranged from 90% to 97% (Table 6).</p><p>&nbsp;</p><p>In studies with adults, data were obtained after two doses of Bexsero with a one month or two-month interval between doses (Table 8).</p><p>&nbsp;</p><p>The vaccination schedules of two doses administered with an interval of one or two months showed similar immune responses in both adults and adolescents. Similar responses were also observed for adolescents administered two doses of Bexsero with an interval of six months.</p><p>&nbsp;</p><p><strong>Table 6. Serum bactericidal antibody responses in adolescents one month after one and two doses of Bexsero administered according to different two-dose schedules and persistence of bactericidal antibody 18 to 23 months after the second dose</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:117%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_33ed8e17-a746-4b6a-846b-3d6bba06f299 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:117%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td><p><strong>Antigen</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>0, 1 months</strong></p></td><td><p><strong>0, 2months</strong></p></td><td><p><strong>0, 6months</strong></p></td></tr><tr><td rowspan="9"><p><strong>fHbp</strong></p></td><td><p>1&nbsp;month after&nbsp;1<sup>st</sup> dose</p></td><td><p>N=677</p></td><td><p>N=342</p></td><td><p>N=112</p></td></tr><tr><td><p>% seropositive*</p><p>(95% CI)</p></td><td><p>94%</p><p>(92‑96)</p></td><td><p>92%</p><p>(88‑94)</p></td><td><p>92%</p><p>(85‑96)</p></td></tr><tr><td><p>hSBA GMT**</p><p>(95% CI)</p></td><td><p>60</p><p>(53‑69)</p></td><td><p>52</p><p>(43‑63)</p></td><td><p>46</p><p>(33‑63)</p></td></tr><tr><td><p>1&nbsp;month after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=638</p></td><td><p>N=319</p></td><td><p>N=86</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>100%</p><p>(99‑100)</p></td><td><p>100%</p><p>(99‑100)</p></td><td><p>100%</p><p>(99‑100)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>210</p><p>(193‑229)</p></td><td><p>234</p><p>(209‑263)</p></td><td><p>218</p><p>(157‑302)</p></td></tr><tr><td><p>18-23 months after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=102</p></td><td><p>N=106</p></td><td><p>N=49</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>82%<br />(74‑89)</p></td><td><p>81%<br />(72‑88)</p></td><td><p>84%<br />(70‑93)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>29<br />(20‑42)</p></td><td style="vertical-align:top"><p>34<br />(24‑49)</p></td><td style="vertical-align:top"><p>27<br />(16‑45)</p></td></tr><tr><td rowspan="9"><p><strong>NadA</strong></p></td><td><p>1&nbsp;month after&nbsp;1<sup>st</sup> dose</p></td><td><p>N=677</p></td><td><p>N=342</p></td><td><p>N=111</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>97%</p><p>(95‑98)</p></td><td><p>96%</p><p>(94‑98)</p></td><td><p>97%</p><p>(92‑99)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>73</p><p>(64‑82)</p></td><td><p>69</p><p>(58‑82)</p></td><td><p>81</p><p>(61‑109)</p></td></tr><tr><td><p>1&nbsp;month after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=639</p></td><td><p>N=320</p></td><td><p>N=86</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>100%</p><p>(99‑100)</p></td><td><p>99%</p><p>(98‑100)</p></td><td><p>99%</p><p>(94‑100)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>490</p><p>(455‑528)</p></td><td><p>734</p><p>(653‑825)</p></td><td><p>880</p><p>(675‑1147)</p></td></tr><tr><td><p>18-23 months after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=102</p></td><td><p>N=106</p></td><td><p>N=49</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>93%<br />(86‑97)</p></td><td style="vertical-align:top"><p>95%<br />(89‑98)</p></td><td style="vertical-align:top"><p>94%<br />(83‑99)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>40<br />(30‑54)</p></td><td style="vertical-align:top"><p>43<br />(33‑58)</p></td><td style="vertical-align:top"><p>65<br />(43‑98)</p></td></tr><tr><td rowspan="9"><p><strong>PorA P1.4</strong></p></td><td><p>1&nbsp;month after&nbsp;1<sup>st</sup></p><p>dose</p></td><td><p>N=677</p></td><td><p>N=342</p></td><td><p>N=111</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>94%</p><p>(92‑96)</p></td><td><p>92%</p><p>(88‑94)</p></td><td><p>90%</p><p>(83‑95)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>49</p><p>(43‑55)</p></td><td><p>40</p><p>(33‑47)</p></td><td><p>42</p><p>(31‑56)</p></td></tr><tr><td><p>1&nbsp;month after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=639</p></td><td><p>N=319</p></td><td><p>N=86</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>100%</p><p>(99‑100)</p></td><td><p>100%</p><p>(99‑100)</p></td><td><p>100%</p><p>(96‑100)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>92</p><p>(84‑102)</p></td><td><p>123</p><p>(107‑142)</p></td><td><p>140</p><p>(101‑195)</p></td></tr><tr><td><p>18-23 months after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=102</p></td><td><p>N=106</p></td><td><p>N=49</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>75%<br />(65-83)</p></td><td style="vertical-align:top"><p>75%<br />(66-83)</p></td><td style="vertical-align:top"><p>86%<br />(73-94)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>17</p><p>(12-24)</p></td><td style="vertical-align:top"><p>19</p><p>(14-27)</p></td><td style="vertical-align:top"><p>27</p><p>(17-43)</p></td></tr><tr><td rowspan="3"><p><strong>NHBA</strong></p></td><td><p>1&nbsp;month after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=46</p></td><td><p>N=46</p></td><td><p>-</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>100%</p><p>(92‑100)</p></td><td><p>100%</p><p>(92‑100)</p></td><td><p>-</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>99</p><p>(76‑129)</p></td><td><p>107</p><p>(82‑140)</p></td><td><p>-</p></td></tr></tbody></table><p>* % seropositive = the percentage of subjects who achieved an hSBA &ge; 1:4.</p><p>** GMT = geometric mean titre.</p><p>&nbsp;</p><p>In the study in adolescents, bactericidal responses following two doses of Bexsero were stratified by baseline hSBA less than 1:4 or equal to or greater than 1:4. Seroresponse&nbsp; rates and percentages of subjects with at least a 4-fold increase in&nbsp; hSBA&nbsp; titre&nbsp; from baseline to one month after the second dose of Bexsero are summarised in Table 7. Following Bexsero vaccination, a high percentage of subjects were seropositive and achieved 4-fold increases in hSBA titres independent of pre-vaccination status.</p><p>&nbsp;</p><p><strong>Table 7. Percentage of adolescents with seroresponse and at least 4-fold rise in bactericidal titres one month after one and two doses of Bexsero administered according to different two-dose schedules - stratified by pre-vaccination titres</strong><!--[if supportFields]><b><span lang=EN-GB style='font-size:
12.0pt;line-height:116%;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span
style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_87a52978-11ed-4c28-b602-8015c659b754
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:116%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><tbody><tr><td><p><strong>Antigen</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>0, 1 months</strong></p></td><td><p><strong>0, 2 months</strong></p></td><td><p><strong>0, 6 months</strong></p></td></tr><tr><td rowspan="8"><p><strong>fHbp</strong></p></td><td rowspan="2"><p>% seropositive* after 1<sup>st</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=388</p><p>90% (87-93)</p></td><td><p>N=193</p><p>86% (80-91)</p></td><td><p>N=65</p><p>86% (75-93)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=289</p><p>100% (98-100)</p></td><td><p>N=149</p><p>99% (95-100)</p></td><td><p>N=47</p><p>100% (92-100)</p></td></tr><tr><td rowspan="2"><p>% 4-fold increase</p><p>after 1<sup>st</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=388</p><p>87% (84-91)</p></td><td><p>N=193</p><p>84% (78-89)</p></td><td><p>N=65</p><p>86% (75-93)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=289</p><p>71% (65-76)</p></td><td><p>N=149</p><p>68% (60-75)</p></td><td><p>N=47</p><p>62% (46-75)</p></td></tr><tr><td rowspan="2"><p>% seropositive after 2<sup>nd</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=369</p><p>100% (98-100)</p></td><td><p>N=179</p><p>100% (98-100)</p></td><td><p>N=55</p><p>100% (94-100)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=269</p><p>100% (99-100)</p></td><td><p>N=140</p><p>100% (97-100)</p></td><td><p>N=31</p><p>100% (89-100)</p></td></tr><tr><td rowspan="2"><p>% 4-fold increase</p><p>after 2<sup>nd</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=369</p><p>100% (98-100)</p></td><td><p>N=179</p><p>100% (98-100)</p></td><td><p>N=55</p><p>100% (94-100)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=268</p><p>90% (86-93)</p></td><td><p>N=140</p><p>86% (80-92)</p></td><td><p>N=31</p><p>90% (74-98)</p></td></tr><tr><td rowspan="8"><p><strong>NadA</strong></p><p><strong>&nbsp;</strong></p></td><td rowspan="2"><p>% seropositive after 1<sup>st</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=454</p><p>95% (93-97)</p></td><td><p>N=223</p><p>96% (92-98)</p></td><td><p>N=79</p><p>96% (89-99)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=223</p><p>100% (98-100)</p></td><td><p>N=119</p><p>98% (94-100)</p></td><td><p>N=32</p><p>100% (89-100)</p></td></tr><tr><td rowspan="2"><p>% 4-fold increase</p><p>after 1<sup>st</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=454</p><p>94% (92-96)</p></td><td><p>N=223</p><p>95% (91-98)</p></td><td><p>N=79</p><p>96% (89-99)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=223</p><p>74% (67-79)</p></td><td><p>N=119</p><p>72% (63-80)</p></td><td><p>N=32</p><p>69% (50-84)</p></td></tr><tr><td rowspan="2"><p>% seropositive after 2<sup>nd</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=427</p><p>100% (99-100)</p></td><td><p>N=211</p><p>99% (97-100)</p></td><td><p>N=64</p><p>98% (92-100)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=212</p><p>100% (98-100)</p></td><td><p>N=109</p><p>100% (97-100)</p></td><td><p>N=22</p><p>100% (85-100)</p></td></tr><tr><td rowspan="2"><p>% 4-fold increase</p><p>after 2<sup>nd</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=426</p><p>99% (98-100)</p></td><td><p>N=211</p><p>99% (97-100)</p></td><td><p>N=64</p><p>98% (92-100)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=212</p><p>96% (93-98)</p></td><td><p>N=109</p><p>95% (90-98)</p></td><td><p>N=22</p><p>95% (77-100)</p></td></tr><tr><td rowspan="8"><p><strong>PorA P1.4</strong></p></td><td rowspan="2"><p>% seropositive after 1<sup>st</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=450</p><p>91% (88-94)</p></td><td><p>N=219</p><p>87% (82-91)</p></td><td><p>N=75</p><p>85% (75-92)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=226</p><p>100% (98-100)</p></td><td><p>N=123</p><p>100% (97-100)</p></td><td><p>N=36</p><p>100% (90-100)</p></td></tr><tr><td rowspan="2"><p>% 4-fold increase</p><p>after 1<sup>st</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=450</p><p>91% (88-94)</p></td><td><p>N=219</p><p>85% (80-90)</p></td><td><p>N=75</p><p>85% (75-92)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=226</p><p>64% (57-70)</p></td><td><p>N=123</p><p>55% (46-64)</p></td><td><p>N=36</p><p>64% (46-79)</p></td></tr><tr><td rowspan="2"><p>% seropositive after 2<sup>nd</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=427</p><p>100% (98-100)</p></td><td><p>N=208</p><p>100% (98-100)</p></td><td><p>N=64</p><p>100% (94-100)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=212</p><p>100% (98-100)</p></td><td><p>N=111</p><p>100% (97-100)</p></td><td><p>N=22</p><p>100% (85-100)</p></td></tr><tr><td rowspan="2"><p>% 4-fold increase after 2<sup>nd</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=426</p><p>99% (98-100)</p></td><td><p>N=208</p><p>100% (98-100)</p></td><td><p>N=64</p><p>100% (94-100)</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=211</p><p>81% (75-86)</p></td><td><p>N=111</p><p>77% (68-84)</p></td><td><p>N=22</p><p>82% (60-95)</p></td></tr><tr><td rowspan="4"><p><strong>NHBA</strong></p></td><td rowspan="2"><p>% seropositive</p><p>after 2<sup>nd</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=2</p><p>100% (16-100)</p></td><td><p>N=9</p><p>100% (66-100)</p></td><td><p>-</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=44</p><p>100% (92-100)</p></td><td><p>N=37</p><p>100% (91-100)</p></td><td><p>-</p></td></tr><tr><td rowspan="2"><p>% 4-fold increase</p><p>after 2<sup>nd</sup> dose</p><p>(95% CI)</p></td><td><p>pre-vaccination titre &lt;1:4</p></td><td><p>N=2</p><p>100% (16-100)</p></td><td><p>N=9</p><p>89% (52-100)</p></td><td><p>-</p></td></tr><tr><td><p>pre-vaccination titre &ge;1:4</p></td><td><p>N=44</p><p>30% (17-45)</p></td><td><p>N=37</p><p>19% (8-35)</p></td><td><p>-</p></td></tr></tbody></table><p>* % seropositive = the percentage of subjects who achieved an hSBA &ge; 1:4.</p><p>&nbsp;</p><p>Antibody persistence data for the study in adolescents were obtained in an extension&nbsp;&nbsp;&nbsp; phase 3 study. At approximately 7.5 years after the two-dose primary series, the percentages of subjects with hSBA &ge; 1:4 declined, ranging across strains from 29% to 84%. The response to a booster dose administered 7.5 years after the primary series was indicative of immunological memory as the percentages of subjects reaching an hSBA &ge; 1:4 across strains ranged from 93% to 100%.</p><p>&nbsp;</p><p>The same study also evaluated antibody persistence data from an additional phase 3 initial study in adolescents. At approximately 4 years after the two-dose primary series, the percentages of subjects with hSBA &ge; 1:5 generally declined from a range across&nbsp;&nbsp; strains of 68% to 100% after the second dose to a range across strains of 9% to 84%. The response to a booster dose administered 4 years after the primary series was indicative of immunological memory as the percentages of subjects with hSBA &ge; 1:5 ranged across strains from 92% to 100%.</p><p><strong>Table 8. Serum bactericidal antibody responses in adults after two doses of Bexsero administered according to different two-dose schedules</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:116%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_c878367e-2041-4c97-aa0d-0d39def51046 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;line-height:116%;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td><p><strong>Antigen</strong></p></td><td><p><strong>&nbsp;</strong></p></td><td><p><strong>0, 1 months</strong></p></td><td><p><strong>0, 2 months</strong></p></td></tr></thead><tbody><tr><td rowspan="3"><p><strong>fHbp</strong></p></td><td><p>1&nbsp;month after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=28</p></td><td><p>N=46</p></td></tr><tr><td><p>% seropositive*</p><p>(95% CI)</p></td><td><p>100%</p><p>(88‑100)</p></td><td><p>100%</p><p>(92‑100)</p></td></tr><tr><td><p>hSBA GMT**</p><p>(95% CI)</p></td><td><p>100</p><p>(75‑133)</p></td><td><p>93</p><p>(71‑121)</p></td></tr><tr><td rowspan="3"><p><strong>NadA</strong></p></td><td><p>1&nbsp;month after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=28</p></td><td><p>N=46</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>100%</p><p>(88‑100)</p></td><td><p>100%</p><p>(92‑100)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>566</p><p>(338‑948)</p></td><td><p>144</p><p>(108‑193)</p></td></tr><tr><td rowspan="3"><p><strong>PorA P1.4</strong></p></td><td><p>1&nbsp;month after&nbsp;2<sup>nd</sup> dose</p></td><td><p>N=28</p></td><td><p>N=46</p></td></tr><tr><td><p>% seropositive</p><p>(95% CI)</p></td><td><p>96%</p><p>(82‑100)</p></td><td><p>91%</p><p>(79‑98)</p></td></tr><tr><td><p>hSBA GMT</p><p>(95% CI)</p></td><td><p>47</p><p>(30‑75)</p></td><td><p>32</p><p>(21‑48)</p></td></tr></tbody></table><p>* % seropositive = the percentage of subjects who achieved an hSBA &ge; 1:4.</p><p>** GMT = geometric mean titre.</p><p>Serum bactericidal response to NHBA antigen has not been evaluated.</p><p><u>&nbsp;</u></p><p><u>Immunogenicity in special populations</u></p><p><em><u>Children and adolescents with complement deficiencies, asplenia, or splenic dysfunction</u></em></p><p>In a phase 3 clinical study, children and adolescents 2 through 17 years of age with complement deficiencies (40), with asplenia or splenic dysfunction (107), and age- matched healthy subjects (85) received two doses of Bexsero two months apart. At 1 month following the 2-dose vaccination course, the percentages of subjects with hSBA &ge;1:5 in individuals with complement deficiencies and asplenia or splenic dysfunction&nbsp;&nbsp; were 87% and 97% for antigen fHbp, 95% and 100% for antigen NadA, 68% and 86%&nbsp;&nbsp;&nbsp; for antigen PorA P1.4, 73% and 94% for antigen NHBA, respectively, indicating an immune response in these immunocompromised subjects. The percentages of healthy subjects with hSBA &ge;1:5 were 98% for antigen fHbp, 99% for antigen NadA, 83% for antigen PorA P1.4, and 99% for antigen NHBA.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Evaluation of pharmacokinetic properties is not required for vaccines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on repeat-dose toxicity and reproductive and developmental toxicity studies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ed1ec2b6-e2b3-484a-9353-7587136d486e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Component</strong></p></td><td style="vertical-align:top"><p><strong>Quantity per 0.5 mL dose</strong></p></td><td style="vertical-align:top"><p><strong>Function</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sodium chloride</p></td><td style="vertical-align:top"><p>3.125 mg</p></td><td style="vertical-align:top"><p>Tonicity adjusting agent</p></td></tr><tr><td style="vertical-align:top"><p>Sucrose</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>Tonicity adjusting agent</p></td></tr><tr><td style="vertical-align:top"><p>Histidine</p></td><td style="vertical-align:top"><p>0.776 mg</p></td><td style="vertical-align:top"><p>Buffering agent</p></td></tr><tr><td style="vertical-align:top"><p>Water for Injection</p></td><td style="vertical-align:top"><p>up to 0.5 mL</p></td><td style="vertical-align:top"><p>Solvent</p></td></tr><tr><td style="vertical-align:top"><p>Aluminium hydroxide</p></td><td style="vertical-align:top"><p>1.5 mg</p></td><td style="vertical-align:top"><p>Adsorbent</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Residues</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_be0125f8-e82a-4fe4-949f-b32f3f816e1e \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b><span
lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Kanamycin (kanamycin is used in early manufacturing process and is removed during the later stages of manufacture. If present, kanamycin levels in the final vaccine are less than 0.01 micrograms per dose)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>Protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>0.5 mL of suspension in a pre-filled syringe (Type I glass) with a plunger stopper (butyl rubber) and with a rubber tip cap.</p><p>The tip cap and rubber plunger stopper of the pre-filled syringe are not made with natural rubber latex.</p><p>Pack sizes of 1 or 10 pre-filled syringes, supplied with or without needles.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Upon storage of the suspension, a fine off-white deposit may form.</p><p>&nbsp;</p><p>Shake the vaccine well before use to form a homogeneous suspension.</p><p>The vaccine should be visually inspected for particulate matter and discoloration prior to administration. In the event of any foreign particulate matter and/or variation of physical aspect being observed, do not administer the vaccine. If two needles of different lengths are provided in the pack, choose the appropriate needle to ensure an intramuscular administration.</p><p>&nbsp;</p><p>&nbsp;</p><p><img src="data:image/png;base64,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" alt="" width="400" height="272" vspace="0" hspace="0" border="0" style="width:400px;height:272px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><u>&nbsp;</u></p><p><u>Disposal:</u></p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>Bexsero is a trademark owned by or licensed to the GSK group of companies.</p><p>&copy; 2023 GlaxoSmithKline group of companies. All rights reserved</p><p><strong>&nbsp;</strong></p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Glaxo Saudi Arabia Ltd.* Jeddah, KSA.
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia.

Manufacturer: 
GSK Vaccines S.r.l.

Bellaria-Rosia, Sovicille, Siena 53018

Italy

Tel: (39) 0577243111     Fax: (39) 0577243401

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS 17
 Date of issue: 11 July 2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>